SECURITIES AND EXCHANGE COMMISION
Washington D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
--------------------
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
--------------------
Date of Report (Date of earliest event reported): October 21,1997
--------------------
Magellan Technology, Inc.
-------------------------
(Exact name of registrant as specified in its charter)
UTAH 0-18271 87-0284979
--------------------------- ---------------------- ------------------
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation) Identification No.)
13526 South 110 West
Draper, Utah 84020
--------------------
(Address of principal executive officers, including zip code)
(801) 495-2211
--------------
(Registrant's telephone number, including area code)
<PAGE>
Item 2. Acquisition of BioSource, Inc.
On October 21, 1997, the Registrant completed a share exchange and
related transactions (collectively, the "Share Exchange") pursuant to an
Agreement and plan of Share Exchange among the Registrant,BioSource, Inc.
("BioSource"), and the holders of all capital stock of BioSource (the
"BioSource Stockholders").
The Share Exchange, consummated on October 21, 1997, included the
following actions and transactions:
(a) The Registrant acquired all of the issued and outstanding shares of
the capital stock of BioSource, Inc. in exchange for the issuance of the
Registrant of 1,500,000 shares of common stock, par value $0.0002 per share,
representing 10% of the Registrant's outstanding common stock ("Common Stock"),
to the BioSource Stockholders; and
(b) $150,000 in cash. $105,000 paid at closing and 45,000 paid in
monthly installments of $7,500 over a six month period beginning
December 1, 1997.
Item 7. Financial Statements and Exhibits.
(a) Financial Statements of business acquired.
The Financial Statements of BioSource required pursuant to
this Item 7(a) are filed as part of this report as pages F-1
through F-10.
(b) Pro forma financial information.
The pro forma financial information of the Registrant and
BioSource required pursuant to this Item 7(b) are filed as part
of this report as pages F-11 through F-15.
(c) Exhibits.
The following exhibits are included herein:
Reg S-K
Exhibit No. Description Exhibit No.
- --------------- -------------------------------------------- ---------------
2 Merger Agreement 1
10 Royalty Agreement 2
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
Magellan Technology, Inc.
/s/ Douglas M. Angus
_______________________
Douglas M. Angus, Vice President
Date: November 3, 1997
<PAGE>
BioSource, Inc.
Financial Statements
For the year ended December 31, 1996
Table of Contents
Page
INDEPENDENT AUDITOR'S REPORT F-1
FINANCIAL STATEMENTS:
Balance Sheet F-2
Statement of Income F-3
Statement of Stockholder's Equity F-4
Statement of Cash Flows F-5
Notes to Financial Statements F-6
<PAGE>
INDEPENDENT AUDITORS' REPORT
To the Board of Directors and Stockholders
of BioSource, Inc.
We have audited the accompanying balance sheet of BioSource, Inc. as of
December 31, 1996, and the related statements of income, stockholders' equity,
and cash flows for the year then ended. These financial statements are the
responsibility of the Company's management. Our responsibility is to express
an opinion on these financial statements based on our audit.
We conducted our audit in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audit provides a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of BioSource, Inc. as of
December 31, 1996, and the results of its operations and its cash flows for
the year then ended in conformity with generally accepted accounting
principles.
TANNER+Co.
Salt Lake City, Utah
August 22, 1997 except for Note 7,
which is dated October 1, 1997
<PAGE>
____________________________________________________________________________
BIOSOURCE, INC.
Balance Sheet
December 31, 1996
____________________________________________________________________________
Assets
------
Current assets:
Cash $ 84,569
Receivables 20,319
-------------
Total current assets 104,888
Property and equipment, net 8,134
-------------
$ 113,022
=============
____________________________________________________________________________
Liabilities and Stockholders' Equity
------------------------------------
Current liabilities:
Accounts payable $ 21,379
Accrued liabilities 52,448
Note payable to related party 24,500
-------------
Total current liabilities 98,327
-------------
Commitments -
Stockholders' equity:
Common stock, no par value, authorized
10,000 shares; issued and outstanding
10,000 shares 12,043
Retained earnings 2,652
-------------
Total stockholders' equity 14,695
-------------
$ 113,022
=============
____________________________________________________________________________
See accompanying notes to financial statements.
F-2
<PAGE>
____________________________________________________________________________
BIOSOURCE, INC.
Statement of Income
Year Ended December 31, 1996
____________________________________________________________________________
Net sales $ 947,798
Cost of goods sold 181,567
-------------
Gross profit 766,231
Selling, general and administrative expenses 487,085
-------------
Income from operations 279,146
Other income (expense):
Loss on disposal of equipment (8,862)
Interest expense (1,624)
-------------
Net income $ 268,660
=============
Pro forma provision for income taxes (91,000)
-------------
Pro forma net income $ 177,660
=============
Earnings per share:
As reported $ 26.87
=============
Pro forma $ 17.77
=============
Weighted average number of common shares 10,000
=============
____________________________________________________________________________
See accompanying notes to financial statements.
F-3
<PAGE>
____________________________________________________________________________
BIOSOURCE, INC.
Statement of Stockholders' Equity
Year Ended December 31, 1996
____________________________________________________________________________
Common Stock Retained
---------------
Shares Amount Earnings Total
------------------------------------
Balance at January 1, 1996 10,000 $ 12,043 $ 173,893 $ 185,936
Distributions - - (439,901) (439,901)
Net income - - 268,660 268,660
------------------------------------
Balance at December 31, 1996 10,000 $ 12,043 $ 2,652 $ 14,695
====================================
____________________________________________________________________________
See accompanying notes to financial statements.
F-4
<PAGE>
____________________________________________________________________________
BIOSOURCE, INC.
Statement of Cash Flows
Year Ended December 31, 1996
____________________________________________________________________________
Cash flows from operating activities:
Net income $ 268,660
Adjustments to reconcile net income to
net cash provided by operating activities:
Depreciation 4,522
Loss on disposal of equipment 8,862
(Increase) decrease in:
Receivables (20,319)
Inventory 11,000
Increase in:
Accounts payable 21,148
Accrued liabilities 21,887
-------------
Net cash provided by
operating activities 315,760
-------------
Cash flows from investing activities-
reduction of related party notes receivable 134,193
-------------
Cash flows from financing activities:
Distributions (439,901)
Net change in note payable to related party (12,125)
-------------
Net cash used in
financing activities (452,026)
-------------
Net decrease in cash (2,073)
Cash, beginning of year 86,642
-------------
Cash, end of year $ 84,569
=============
Supplemental disclosure of cash flow information
Cash paid during the year ended December 31,
1996 for:
Interest $ 1,740
=============
Income taxes $ -
=============
__________________________________________________________________________
See accompanying notes to financial statements.
F-5
<PAGE>
BIOSOURCE, INC.
Notes to Financial Statements
December 31, 1996
- ----------------------------------------------------------------------------
1. Summary of Significant Accounting Policies
Organization and Concentration of Credit Risk
BioSource, Inc., (the Company) is incorporated under the laws of the state of
Utah and is primarily engaged in manufacturing and distributing a medical
device used in the health care industry. The device uses customized computer
software developed by the Company.
Financial instruments which potentially subject the Company to concentration
of credit risk consist primarily of trade receivables. In the normal course
of business, the Company provides credit terms to its customers. Accordingly,
the Company performs ongoing credit evaluations of its customers and maintains
allowances for possible losses which, when realized, have been within the
range of management's expectations.
The Company maintains its cash in bank deposit accounts which, at times, may
exceed federally insured limits. The Company has not experienced any losses
in such accounts and believes it is not exposed to any significant credit risk
on cash and cash equivalents.
Revenue Recognition
Revenue is recognized upon shipment of the product or when services are
provided.
Cash and Cash Equivalents
For purposes of the statement of cash flows, the Company considers all highly
liquid debt instruments with a maturity of three months or less to be cash
equivalents.
Property and Equipment
Property and equipment are recorded at cost, less accumulated depreciation.
Depreciation and amortization on property and equipment is determined using
the straight-line method over the estimated useful lives of the assets.
Expenditures for maintenance and repairs are expensed when incurred and
betterments are capitalized. Gains and losses on sale of property and
equipment are reflected in net income.
Income Taxes
The Company has elected to be taxed as an S corporation under the Internal
Revenue Code. This election, with certain exceptions, stipulates that
stockholders of the Company are responsible to pay the income taxes on their
respective share of the Company's taxable income. Therefore, no provision or
liability for income taxes is included in the financial statements.
F-6
<PAGE>
BIOSOURCE, INC.
Notes to Financial Statements
Continued
- ----------------------------------------------------------------------------
1. Summary of Significant Accounting Policies Continued
Use of Estimates in the Preparation of Financial Statements
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates.
2. Receivables
Receivables consists of the following:
Trade accounts receivable $ 15,576
Related party receivables 4,743
----------
$ 20,319
==========
Related party receivables consist of shareholder advances totaling $599 (see
note 5), employee advances totaling $944 and a receivable from a relative of a
shareholder totaling $3,200.
F-7
<PAGE>
BIOSOURCE, INC.
Notes to Financial Statements
Continued
- ----------------------------------------------------------------------------
3. Property and Equipment
Property and equipment consists of the following:
Furniture and equipment $ 37,439
Lab equipment 9,221
----------
46,660
Less accumulated depreciation (38,526)
----------
$ 8,134
==========
4. Related Party Transactions
Storage Space
The Company has an agreement to pay each shareholder $100 per month in
exchange for storage of Company records and equipment. Rent expense related
to this agreement totaled $3,600 for the year ended December 31, 1996. The
agreement expires August 31, 1997.
Note Payable to Related Party
The note payable to related party consists of a note payable to a relative of
certain shareholders, the note is due on demand, with simple interest at 10%,
and is unsecured. At December 31, 1996, the note had a balance due of
$24,500.
5. Commitments
Shareholder Advances
The Company has agreements to provide advances to its shareholders up to a
maximum of $100,000 for two of the shareholders and $50,000 for the other
shareholder. The advances are to be repaid each year on December 31, with
interest at the annual short-term Applicable Federal Rate (AFR). At December
31, 1996, shareholder advances totaled $599 and are included in receivables
(see note 2).
F-8
<PAGE>
BIOSOURCE, INC.
Notes to Financial Statements
Continued
- ----------------------------------------------------------------------------
5. Commitments - Continued
Operating Leases
The Company is obligated under certain operating leases for office space and
equipment. Total lease expense for the year ended December 31, 1996 was
approximately $9,000. Future minimum lease payments under noncancellable
operating leases with initial terms of one year or more are as follows at
December 31, 1996:
Year Ending December 31,
1997 $ 15,870
1998 11,520
1999 6,814
2000 963
----------
$ 35,167
==========
6. Fair Value of Financial Instruments
All financial instruments are held for purposes other than trading. The
Company estimates that the fair value of all financial instruments at December
31, 1996, does not differ materially from the aggregate carrying values of its
financial instruments recorded in the accompanying balance sheet. The
estimated fair value amounts have been determined by the Company using
available market information and appropriate valuation methodologies.
Considerable judgement is necessarily required in interpreting market data to
develop the estimates of fair value, and, accordingly, the estimates are not
necessarily indicative of the amounts that the Company could realize in a
current market exchange.
7. Subsequent Events
On October 1, 1997, the shareholders of the Company entered into an agreement
to sell all of their shares to another Company.
On March 14, 1997, the Company entered into a note payable agreement with a
bank for $25,050. The note bears interest at 10.25% and matures on March 14,
1998, at which time all principal and accrued unpaid interest is due.
Quarterly payments of interest are due beginning June 14, 1997.
F-9
<PAGE>
BIOSOURCE, INC.
Notes to Financial Statements
Continued
- ----------------------------------------------------------------------------
8. Pro Forma Information
The statement of income reflects operations of the Company as an S
corporation, however, as part of the ownership change (see Note 7), the
Company will become a tax paying entity, therefore, the pro forma effects of
this change are reflected as additional information.
F-10
<PAGE>
MAGELLAN TECHNOLOGY, INC.
Pro Forma Condensed Combined Financial Statements
(Unaudited)
The following unaudited condensed pro forma combined balance sheet at
September 30, 1997 and the proforma combined statements of operations for
the year ended December 31, 1996 and the nine months ended September 30,
1997 of Magellan Technology, Inc. ("Magellan") and BioSource, Inc.
("BioSource"), respectively, assumes the acquisition of BioSource by
Magellan. It combines the historical balance sheets of BioSource and
Magellan. The business combination has been accounted for as a purchase of
BioSource giving effect to the acquisition of the outstanding common shares
of BioSource. The unaudited condensed pro forma balance sheet should be
read in conjunction with the historical financial statements and related
notes.
The following unaudited condensed pro forma combined statements of
operations for the year ended December 31, 1996 and nine months ended
September 30, 1997 for Magellan and BioSource, respectively, assumes the
acquisition of BioSource by Magellan as of the beginning of the year and
nine months, respectively.
The pro forma results of operations are not necessarily indicative of
the results of operations that would actually have been obtained if the
transactions had occurred as of the beginning of the year and nine month
periods. These statements should be read in conjunction with the
historical financial statements and related notes.
F-11
<PAGE>
CONSOLIDATED MAGELLAN TECHNOLOGY, INC.
Pro forma Condensed Combined Balance Sheet (Unaudited)
September 30, 1997
<TABLE>
<S> <C> <C> <C> <C> <C>
Magellan
Technology BioSource PRO FORMA
Incorporated Incorporated Total Adjustments Combined
------------ ------------ ----------- ------------ -----------
Current Assets 421,969 98,300 520,269 (105,000)(1),(2) 415,269
Investment in SIS, LLC 1,459,682 1,459,682 1,459,682
Property Plant & Equipment - Net 95,039 12,967 108,006 108,006
Other Assets 31,140 31,140 652,473 (1),(2) 683,613
------------ ------------ ----------- ------------ -----------
Total Assets 1,976,690 142,407 2,119,097 547,473 2,666,570
============ ============ =========== ============ ===========
Current Liabilities 1,983,619 89,880 2,073,499 45,000 (1),(2) 2,118,499
Long Term Liabilities 522,187 522,187 522,187
------------ ------------ ----------- ------------ -----------
Total Liabilities 2,505,806 89,880 2,595,686 45,000 2,640,686
------------ ------------ ----------- ------------ -----------
Common Stock:
Magellan Technology, Inc. 2,724 2,724 300 (1),(2) 3,024
BioSource, Inc. 12,043 12,043 (12,043)(1),(2) -
Additional Paid-in Capital 6,316,853 6,316,853 554,700 (1),(2) 6,871,553
Retained Earnings (Deficit) (6,848,693) 40,484 (6,808,209) (40,484)(1),(2)(6,848,693)
------------ ------------ ----------- ------------ -----------
Total Stockholders' Equity
(Deficit) (529,116) 52,527 (476,589) 502,473 25,884
------------ ------------ ----------- ------------ -----------
Total Liabilities and Stockholders'
Equity 1,976,690 142,407 2,119,097 547,473 2,666,570
============ ============ =========== ============ ===========
</TABLE>
F-12
<PAGE>
CONSOLIDATED MAGELLAN TECHNOLOGY, INC.
Pro forma Condensed Combined Statement of Operations (Unaudited)
Nine Months Ended September 30, 1997
<TABLE>
<S> <C> <C> <C> <C> <C>
Magellan
Technology BioSource PRO FORMA
Incorporated Incorporated Total Adjustments Combined
------------ ------------ ----------- ------------ -----------
Sales 661,626 661,626 661,626 661,626
Costs and Expenses:
Operating 143,877 143,877 143,877 143,877
Selling, General &
Administrative 844,803 302,344 1,147,147 1,147,147
Research and Development 499,103 499,103 499,103
Depreciation and Amortization 13,221 3,281 16,502 16,502
------------ ------------ ----------- ------------ -----------
Income (loss) from operations (1,357,127) 212,124 (1,145,003) - (1,145,003)
Other Income (Expense)
Earnings / (Loss) from
Investment in SIS, LLC (9,251) (9,251) (9,251)
Interest Expense (92,446) 1,791 (90,655) (90,655)
Other Income (Expense) (7,038) (7,038) (7,038)
------------ ------------ ----------- ------------ -----------
Net Loss (1,465,862) 213,915 (1,251,947) - (1,251,947)
============ ============ =========== ============ ===========
Net Loss per Share (0.10) (0.08)
Weighted Average Number of Common
Shares Outstanding 14,448,893 15,948,893
============ ===========
</TABLE>
F-13
<PAGE>
CONSOLIDATED MAGELLAN TECHNOLOGY, INC.
Pro forma Condensed Combined Statement of Operations (Unaudited)
Year Ended December 31, 1996
<TABLE>
<S> <C> <C> <C> <C> <C>
Magellan
Technology BioSource PRO FORMA
Incorporated Incorporated Total Adjustments Combined
------------ ------------ ----------- ------------ -----------
Sales 1,150,046 947,798 2,097,844 2,097,844
Costs and Expenses:
Operating 742,759 181,567 924,326 924,326
Selling, General &
Administrative 528,381 482,563 1,010,944 1,010,944
Research and Development
Depreciation and Amortization 104,296 4,522 108,818 108,818
------------ ------------ ----------- ------------ -----------
Income (loss) from operations (225,390) 279,146 53,756 - 53,756
Other Income (Expense)
Earnings / (Loss) from
Investment in SIS, LLC (86,804) (86,804) (86,804)
Purchased in-process Research
and Development (2,557,114) (2,557,114) (2,557,114)
Interest Expense (47,644) (1,624) (49,268) (49,268)
Other Income (Expense) (4,427) (8,862) (13,289) (13,289)
------------ ------------ ----------- ------------ -----------
Net Loss (2,921,379) 268,660 (2,652,719) - (2,652,719)
============ ============ =========== ============ ===========
Net Loss per Share (0.33) (0.25)
============ ===========
Weighted Average Number of Common
Shares Outstanding 8,984,000 10,484,000
============ ===========
</TABLE>
F-14
<PAGE>
MAGELLAN TECHNOLOGY, INC.
Notes to Pro Forma Condensed Combined Financial Statements
(Unaudited)
Year Ended December 31, 1996 and Nine Months Ended September 30, 1996
Pro Forma Adjustments
(1) Magellan issued common stock and $150,000 cash to acquire the
common stock of BioSource. The Magellan common stock was issued
to the existing BioSource shareholders on a basis of 150 shares of
Magellan for every 1 share of BioSource held. The value of the Magellan
common stock plus the cash was in excess of the fair market value of
BioSource assets at the acquisition date by $652,473. This amount was
recorded as goodwill.
(2) Reflects the elimination of the investment in BioSource with the
BioSource equity to complete the consolidation.
F-15
MERGER AGREEMENT
MAGELLAN TECHNOLOGY, INC.
PROHEALTH, INC.
and
BIOSOURCE, INC.
<PAGE>
MERGER AGREEMENT
This MERGER AGREEMENT, dated as of the 1st day of October 1997, among
MAGELLAN TECHNOLOGY, INC., a Utah corporation ("Magellan"), PROHEALTH, INC., a
Utah corporation and a wholly owned subsidiary of Magellan ("ProHealth"),
BIOSOURCE, INC., a Utah corporation (the "Company"), JAMES H. CLARK, an
individual residing at 432 North 750 East, Lindon, Utah 84042, JOE S.
GALLOWAY, an individual residing at 1636 North Murdock Dr., Pleasant Grove,
Utah 84062, and WILLIS H. CLARK, an individual residing at 1065 North 1500
West, Provo, Utah 84604.
RECITALS:
--------
WHEREAS, each Stockholder (as defined below) owns the number and class
of shares of Company Stock (as defined below) set forth opposite its name on
Schedule 2.6, which represents 100% of the issued and outstanding shares of
capital stock of the Company; and
WHEREAS, the parties hereto desire that the Company be merged with and
into ProHealth, with ProHealth being the surviving corporation, pursuant to
the terms and provisions of this Agreement; and
WHEREAS, for federal income tax purposes, the parties intend that such
merger qualify as reorganization pursuant to Section 368(a)(1)(A) and
368(a)(2)(D) of the Code (as defined below);
NOW, THEREFORE, in consideration of the premises, the mutual covenants,
representations and warranties made herein and the mutual benefits to be
derived herefrom, the parties hereto agree as follows:
ARTICLE 1
THE MERGER
1.1 The Merger.
----------
(a) At the Effective Time, in accordance with the provisions of
this Agreement and the RUBCA, the Company shall be merged with and into
ProHealth, and ProHealth shall be the Surviving Corporation of the Merger and
shall continue its corporate existence under the laws of the state of Utah
under the name ProHealth, Inc. At the Effective Time, the separate existence
of the Company shall cease.
(b) At the Effective Time, the Surviving Corporation shall
possess all rights, privileges, immunities, powers, franchises, properties and
assets of the Company and ProHealth, and shall become liable for all the
debts, liabilities and duties of the Company and ProHealth to the same extent
as if said debts, liabilities and duties had been incurred or contracted by
it, all as provided in Section 1106 of the RUBCA.
1
<PAGE>
1.2 Articles of Incorporation. The Articles of Incorporation of the
-------------------------
Surviving Corporation shall be the Articles of Incorporation of ProHealth as
in effect at the Effective Time of the Merger until amended in accordance with
the provisions thereof and as provided in the RUBCA.
1.3 Bylaws. The Bylaws of the Surviving Corporation shall be the
------
Bylaws of ProHealth as in effect immediately prior to the Effective Time,
until amended in accordance with the provisions thereof and as provided by the
RUBCA.
1.4 Directors & Officers. The initial directors of the Surviving
--------------------
Corporation shall be William A. Fresh, Richard C. Winwood, Darwin Millet and
Reginald Hughes. The initial officers of the Surviving Corporation shall be
William Fresh, Chief Executive Officer, and Reginald Hughes, President and
Chief Operating Officer. The officers and directors of the Surviving
Corporation named in this Section 1.4, shall hold office from the Effective
Time in accordance with the Articles of Incorporation and Bylaws of the
Surviving Corporation until the earlier of their death, resignation or
removal.
1.5 Treatment of the Capital Stock.
------------------------------
(a) Each share of the common stock of ProHealth outstanding at
the Effective Time shall continue to be one share of common stock of the
Surviving Corporation.
(b) The 10,000 shares of Company Stock issued and outstanding at
the Effective Time, constituting all of the issued and outstanding capital
stock of the Company at the Effective Time, shall be converted by virtue of
the Merger and without any action on the part of the holders thereof, into:
(i) an aggregate of 1,500,000 shares of Magellan Stock,
which constitutes a conversion ratio of 150 shares of Magellan Stock for each
share of Company Stock to be converted (the "Share Conversion Amount");
provided, however, that the aggregate number of shares of Magellan Stock that
each of the stockholders of the Company shall be entitled to receive shall be
rounded to the nearest whole number in the event of fractions (with 0.5 being
rounded up), and no cash payment shall be made with respect to any fractional
share; and
(ii) the right to receive an aggregate of $150,000, or $15
for each share of Company Stock, which shall be paid to each Stockholder as
set forth in Section 1.6(d).
(c) At the Effective Time, each holder of a certificate or
certificates representing shares of issued and outstanding Company Stock shall
surrender such certificate or certificates to Magellan and upon surrender, be
entitled to receive in exchange therefor a certificate or certificates
representing the number of whole shares of Magellan Stock which the Company
Stock theretofore represented by the certificate or certificates so
surrendered shall have been converted pursuant to the Share Conversion Amount;
provided, however, that the number of shares of Magellan Stock which each
- -------- -------
Stockholder shall be required to deposit with the Escrow Agent pursuant to an
Escrow Agreement between the Stockholders and Magellan shall be withheld by
2
<PAGE>
the exchange agent and issued to the Escrow Agent, to be later released to the
Stockholders pursuant to and in accordance with the Escrow Agreement and to
the extent such shares have not been cancelled as a result of the failure of
the business of the Company to meet the sales projections set forth in
Schedule 1.7 or have not been made subject to claims of Magellan against the
Company and/or the Stockholders pursuant to and in accordance with this
Agreement and the Escrow Agreement.
1.6 Closing. The Closing of the Merger will take place at the offices
-------
of Magellan at 13526 South 110 West, Draper, Utah, beginning at 8:00 a.m.
(Salt Lake City time) on the date which is as soon as reasonably possible
after all of the conditions required to be satisfied in Articles 6 and 7 have
been fulfilled or waived, but in no event later than October 31, 1997. Such
date may be extended by mutual agreement of the parties. At the Closing:
(a) ProHealth and the Company shall cause the Articles of Merger
and Plan of Merger in the form attached hereto as Exhibit A, together with any
other documents required by applicable law to effect the Merger, to be filed
and recorded with the Division of Corporations and Commercial Code of the
Department of Commerce of the State of Utah in accordance with the provisions
of the RUBCA and shall take any other lawful actions and do any and all other
lawful things necessary to cause the Merger to become effective, in accordance
with the provisions the RUBCA. The Merger will be effective at the Effective
Time;
(b) The Stockholders will deliver to Magellan free and clear of
any Liens, the certificates identified on Schedule 2.6 representing all of the
outstanding Company Stock, duly endorsed in blank or accompanied by stock
powers or other instruments of transfer duly endorsed in blank, and bearing or
accompanied by all requisite stock transfer stamps;
(c) Magellan shall issue to the Stockholders the number of
shares of Magellan Stock calculated in accordance with the Share Conversion
Amount in exchange for the Company Stock so delivered by the Stockholders by
delivery of one or more certificates to each Stockholder for the aggregate
number of shares of Magellan Stock that such Stockholder is entitled to
receive, as set forth in Section 1.5(b) hereof, provided that Magellan shall
deliver to the Escrow Agent, in lieu of delivery to the Stockholders,
certificates for the number of shares to be held in escrow by the Escrow Agent
in accordance with Section 1.7; and
(d) The cash payment to be made to the Stockholders shall be
paid to the Stockholders as follows:
(i) At the Closing, Magellan will deliver to each of the
Stockholders a cash payment in the amount of $35,000.
(ii) Beginning December 1, 1997 and continuing thereafter
on the first day of each month through and including May 1, 1998, Magellan
will deliver to each of the Stockholders six equal monthly cash payments in
the amount of $2,500.
3
<PAGE>
(e) The parties shall deliver such certificates and other
documents required to be delivered under Articles 6 and 7 hereof.
1.7 Escrow. As soon as practicable following the Closing, Magellan
------
will deliver to the Escrow Agent certificates representing 300,000 shares of
the Magellan Stock to be issued in connection with the Merger taken
proportionately from the Magellan Stock that each Stockholder is entitled to
receive pursuant to Section 1.5. Such shares will be held in escrow, pursuant
to the terms and conditions of the Escrow Agreement, which (i) shall provide
for cancellation of such shares to the extent sales from the business
operations of the Company being acquired in the merger for the six month
period ending March 31, 1998 are less than the sales projections for such
period as set forth in Schedule 1.7 attached hereto on the terms set forth in
the Escrow Agreement and (ii) shall secure the indemnification obligations of
the Stockholders set forth in Section 9.1. The shares held in escrow will
represent shares to which the Stockholders would otherwise be entitled to
receive pursuant to Section 1.5. Such delivery will be made on behalf of, and
as a convenience to, the Stockholders with the same force and effect as though
such shares had been delivered directly to the Stockholders and subsequently
delivered by the Stockholders to the Escrow Agent.
ARTICLE 2
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
AND EACH OF THE STOCKHOLDERS
The Company and each Stockholder, jointly and severally, represents and
warrants to Magellan and ProHealth that the following representations and
warranties are true and correct on the date hereof and on the Closing Date:
2.1 Organization and Standing. The Company is a corporation, duly
-------------------------
organized, validly existing and in good standing under the laws of the State
of Utah. The Company (i) has all necessary power and authority to own, lease
or license its property and to conduct its business as now conducted and (ii)
is duly qualified or licensed to do business in all jurisdictions where the
nature of its business or the properties owned or leased by it makes such
qualification or licensing necessary, except where the failure so to qualify
would not have a Material Adverse Effect on the Company. Schedule 2.1 sets
forth (A) a list of each jurisdiction in which the Company is qualified or
licensed to do business as a foreign corporation and (B) a list of each state
where the Company owns and/or leases property.
2.2 Articles of Incorporation, Bylaws and Minute Books. Correct and
--------------------------------------------------
complete copies of the Articles of Incorporation and Bylaws of the Company
have been delivered to Magellan. The minute book of the Company has been made
available to and at that time contained and now contains true and complete
minutes and records (to the extent that any such minutes or records exist) of
all meetings, proceedings and other actions of the Company's present and
former stockholders and boards of directors from the date of its organization
4
<PAGE>
to the date hereof and all such meetings, proceedings and actions have been
duly, legally and properly held or taken.
2.3 Authorization, Execution and Enforceability. The Company has the
-------------------------------------------
corporate authority to execute and deliver this Agreement and the agreements
related hereto, to perform its obligations hereunder and thereunder and to
consummate the transactions contemplated hereby and thereby. Such execution,
delivery and performance have been duly authorized by the Board of Directors
of the Company, and all other necessary corporate action of the Company has
been taken including all shareholder action necessary to approve the
transactions contemplated hereby. This Agreement has been, and the agreements
related hereto will be upon execution and delivery thereof, duly executed and
delivered by the Company. This Agreement does, and upon their execution and
delivery each of the related agreements will, constitute the legal, valid and
binding obligation of the Company enforceable against it in accordance with
its respective terms, except as such enforceability may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium or similar laws
affecting the enforcement of creditors' rights generally.
2.4 Consents. Except as set forth in Schedule 2.4, no consent under
--------
any indenture, contract, instrument or other agreement to which the Company is
a party, is required to be obtained in connection with the execution, delivery
and performance by the Company of this Agreement or the agreements related
hereto. Except as set forth in Schedule 2.4, there are no consents,
approvals, permits, certificates, tariffs or authorizations, declarations,
filings or registrations with, or notices to, any governmental or regulatory
authority required to be made or obtained by the Company in connection with
the execution and delivery of this Agreement and the agreements related hereto
and the performance of the transactions contemplated hereby and thereby,
except where the failure to obtain such consent, approval or authorization or
make such declaration, filing or registration, or give such notice, would not
have a Material Adverse Effect on the Company.
2.5 Non-Contravention. Except as set forth in Schedule 2.5, the
-----------------
execution, delivery and performance of this Agreement and the agreements
related hereto by the Company will not breach or violate any provision of, or
cause any event by which a right of termination or acceleration or Lien on any
of its respective properties would arise under: (i) any statute or regulation
or any order of any court or other agency of government or any judgment, award
or decree; (ii) the Articles of Incorporation or Bylaws of the Company, or
(iii) any indenture, contract, instrument, license or other agreement by which
the Company is a party or is bound.
2.6 Capitalization.
--------------
(a) The authorized capital stock of the Company consists of
10,000 shares Common Stock, no par value per share. Section (a) of Schedule
2.6 sets forth a true and complete list of each holder of Company Stock and
the number and class of shares held by such Person. Each holder of Company
Stock set forth on Schedule 2.6 is the record and beneficial owner of and has
good and valid title to the number and class of shares set forth opposite its
name. Section (b) of Schedule 2.6 sets forth a list of all outstanding grants
of options and warrants and the holders of such options and warrants.
5
<PAGE>
(b) Except as set forth in Schedule 2.6, there are no (i)
outstanding or authorized common or preferred shares or other capital stock,
options, warrants, rights, contracts, rights of first refusal or first offer,
calls, puts, rights to subscribe, conversion rights, or other agreements or
commitments to which the Company is a party or which are binding upon the
Company providing for the issuance, disposition, or acquisition of any shares
of Company Stock or other capital stock of the Company; (ii) outstanding or
authorized stock appreciation, phantom stock, or similar rights; (iii)
contractual or statutory preemptive rights or similar restrictions with
respect to the issuance of any shares of Company Stock or other capital stock
of the Company; and (iv) voting trusts, proxies, or any other agreements,
restrictions or understandings with respect to the voting of Company Stock or
any other voting securities of the Company.
2.7 Subsidiaries: Investments. The Company does not have any
--------------------------
Subsidiaries. The Company does not, directly or indirectly, own any shares of
stock or any other security or interest in any corporation, partnership,
association or joint venture.
2.8 Company Financial Statements.
----------------------------
(a) The Company Financial Statements and Interim Financial
Statements (i) are, in each case, true, complete and accurate in all material
respects, (ii) have been prepared in conformity with generally accepted
accounting principals ("GAAP") consistently applied, and (iii) in the case of
each such balance sheet, fairly presents the financial condition of the
Company as at its respective date and, in the case of each such statements of
income and retained earnings and statement of cash flows, fairly presents the
results of the Company's operations on a consolidated basis and its cash flows
for the periods covered thereby.
(b) The Interim Financial Statements have been certified by the
Company's President and Chief Financial Officer in their capacity as officers
of the Company as presenting fairly, in accordance with GAAP applied on a
basis consistent with prior fiscal periods, the financial condition and
results of operations of the Company.
2.9 Conduct of Business; Records and Books of Account. The Company
-------------------------------------------------
has conducted its business in the ordinary course, consistent with past
practice, since its incorporation. The records and books of account of the
Company have been regularly kept and maintained in conformity with GAAP
applied on a consistent basis with preceding years, subject only to normal
year-end adjustments.
2.10 Absence of Undisclosed Liabilities, Except as otherwise set forth
----------------------------------
on Schedule 2.10, the Company has no material liabilities, debts or
obligations, whether contingent or absolute, direct or indirect, known or
unknown, or matured or unmatured, including, without limitation, liabilities
on account of Taxes, other government charges or Claims that may be
subsequently brought, not shown or provided for in the Interim Balance Sheet
(and to the knowledge of the Company, there is no basis for any present or
future Claim against the Company giving rise to any liability), except those
(i) set forth on the Interim Financial Statements and (ii) incurred since the
Interim Financial Statements Date in the ordinary course of business of the
Company and which would not, individually or in the aggregate, have or
reasonably be expected to have a Material Adverse Effect on the Company.
6
<PAGE>
2.11 Taxes.
-----
(a) The Company has filed or caused to be filed on a timely
basis all Returns that are or were required to be filed by it. The Company
has delivered to Magellan copies of, and Schedule 2.11 contains a complete and
accurate list of, all such Returns relating to income or franchise taxes filed
since January 1, 1994. The Company has paid all Taxes required to be paid
including, without limitation, those Taxes shown to be due on such Returns or
that have or may have otherwise become due and such Returns are true, correct,
and complete. The Company has never filed, or been required to file, any
Returns as a member of an affiliated group, nor does it have any liability for
Taxes of any Person under Treasury Regulation section 1.1502-6 (or any similar
provision of state, local, foreign or other law) as a transferee or successor
by contract or otherwise. No claim has ever been made by an authority in any
jurisdiction where the Company does not file Returns that the Company may be
subject to taxation by such jurisdiction.
(b) Except as set forth on Section (b) of Schedule 2.11, the
federal and state income Tax Returns of the Company have not been audited by
the Internal Revenue Service or relevant state tax authorities. Except as
described in Section (b) of Schedule 2.11, the Company has not given or been
requested to give waivers or extensions (or is or would be subject to a waiver
or extension given by any other Person) of any statute of limitations relating
to the payment of Taxes of the Company or for which the Company may be liable.
(c) The charges, accruals, and reserves with respect to Taxes on
the respective books of the Company are adequate (determined in accordance
with GAAP) and are at least equal to the Company's liability for Taxes. There
exists no proposed tax assessment against the Company except as disclosed in
the Balance Sheet or in Section (c) of Schedule 2.11. No consent to the
application of Section 341(f)(2) of the Code has been filed with respect to
any property or assets held, acquired, or to be acquired by the Company. All
Taxes that the Company is or was required to withhold or collect have been
duly withheld or collected and, to the extent required, have been paid to the
proper governmental body or other Person.
2.12 Good and Marketable Title. Except as set forth in Schedule 2.12,
-------------------------
the Company has good and marketable title, free and clear of any Liens (other
than Permitted Liens) whatsoever, to: (i) all of its material assets and
property including, without limitation, all software and related intellectual
material used in the operation and conduct of its business and all assets
shown on the Company Balance Sheet and the Interim Balance Sheet in the
amounts and categories set forth therein, and (ii) all of the material assets
acquired by the Company since incorporation. The transactions contemplated by
this Agreement and the agreements related hereto will not effect a termination
of, or otherwise interfere with, the ownership of any or all of such assets by
the Company.
2.13 Fixed Assets: Sufficiency of Assets.
-----------------------------------
(a) Section (a) of Schedule 2.13 sets forth a true and correct
list of: (i) all real property, motor vehicles, and computer equipment owned
by the Company on the date hereof; (ii) all other equipment, furniture,
fixtures and other fixed assets owned by the Company on the date hereof, the
original cost of which was in excess of $1,000 in each instance; and (iii) the
cost (and tax basis if other than cost), accumulated depreciation, and method
of depreciation employed with respect to all such fixed assets.
7
<PAGE>
(b) The tangible and intangible assets of the Company whether
owned, licensed or leased by it, are sufficient to provide all goods and
services currently offered or committed by the Company to its customers and
such tangible assets are in good condition and free from defects other than
those that would not have or reasonably be expected to have a Material Adverse
Effect on the Company. There are no assets or property necessary for the
conduct of the business of the Company, as presently utilized or conducted
that are not currently owned, leased, or licensed by the Company.
2.14 Leased Properties. Schedule 2.14 sets forth a true and correct
-----------------
list of all outstanding realty and personalty leases to which the Company is a
party or by which it is bound, whether as lessee or lessor, on the date
hereof. The Company occupies or uses all of the real and personal property
leased by it under and in accordance with such leases, and has neither
assigned its interests under any such lease nor further subleased the property
that is the subject of any such lease. All of such leases are in full force
and effect and there exists no default or event, occurrence, condition or act
that, with the giving of notice, the lapse of time or both, would become a
default thereunder.
2.15 Licensed Properties. Section (a) of Schedule 2.15 sets forth a
-------------------
true and correct list of all outstanding licenses to which the Company is a
party or by which it is bound, whether as licensee or licensor, on the date
hereof (including without limitation any software licenses other than
commercial, off-the-shelf software used in the ordinary course of business),
and a true and complete copy of each such license has been delivered to
Magellan. Except as set forth in Section (b) of Schedule 2.15, the Company
has the right to use all of the property licensed by it under any such
licenses, and any license granted by the Company to any third party is non-
exclusive and any such licensees are not and will not be entitled to further
sublicense, assignment or transfer the licensed property to others. All such
licenses are in full force and effect and there exists no default or event or
condition or act that, with the giving of notice, the lapse of time or both,
would become a default thereunder.
2.16 Patents, Copyrights, and Other Proprietary Rights.
-------------------------------------------------
(a) The Company owns all right, title, and interest, in or to,
or has a legal, valid, binding and enforceable license to use, all trademarks,
tradenames, service marks, logos, patents and copyrights, including
applications therefor, inventions, formulas, methods, software, computer
programs, trade secrets, processes and proprietary systems and any and all
other proprietary rights (all such items being referred to as the
"Intellectual Property") necessary to the conduct or operation of its
business, or heretofore or presently used by the Company in connection with
its business. Each item of Intellectual Property owned or used by the Company
immediately prior to the Effective Time hereunder will be owned or available
for use by the Surviving Corporation on identical terms and conditions
immediately subsequent to the Effective Time. The Company has taken all
necessary and desirable action to protect each item of Intellectual Property
that the Company owns or uses.
8
<PAGE>
(b) Section (a) of Schedule 2.16 sets forth a true and correct
list of all trademarks, trade names, service marks, patents and copyrights
(and applications therefor), heretofore or presently used by the Company in
connection with its business, and a true and complete copy of each instrument
evidencing any such trademark, trade name, service mark, patent and copyright
(or application therefor), has been delivered to Magellan. Section (b) of
Schedule 2.16 also sets forth a list of all registries, including the United
States Patent and Trademark Office and United States Copyright Office, where
any of the foregoing is registered or subject to a pending application for
registration.
(c) Section (c) of Schedule 2.16 identifies each item of
Intellectual Property (other than that disclosed pursuant to Section 2.16(b)
that the Company owns and which is material to the conduct of its business and
any item of Intellectual Property that any third party owns and that the
Company uses pursuant to license, sublicense, agreement, or permission (other
than "off-the-shelf" software purchased for use in the day-to-day operations
of the Company) which is material to the conduct of the Company's business.
The Company has supplied the Company with correct and complete copies of all
written documentation evidencing ownership and prosecution (if applicable) of
such Intellectual Property or the licenses, sublicenses, agreements, and
permissions (as amended to date) pursuant to which the Company license such
Intellectual Property.
(d) None of the Intellectual Property is subject to any
outstanding judgment, order, decree, stipulation, injunction, or charge, and
no charge, complaint, action, suit, proceeding, hearing, investigation, claim,
or demand is pending, or, to the knowledge of the Company (and employees with
responsibility for Intellectual Property matters), is threatened which
challenges the legality, validity, or enforceability of any item of
Intellectual Property.
(d) Except as set forth in Section (c) to Schedule 2.16, the
Company has the sole and exclusive right to use the Intangible Property and
the Company has not entered into any licenses, sublicenses, or agreements
relating to the use by any other Person of any Intellectual Property. Except
as set forth on Section (c) to Schedule 2.16, no royalty or fees are payable
by the Company to any Person by reason of ownership or use of the Intellectual
Property.
(e) The Company has not interfered with, infringed upon,
misappropriated, or otherwise come into conflict with any Intellectual
Property rights of third parties, and none of the Stockholders or the
directors and officers (and employees with responsibility for Intellectual
Property matters) of the Company has ever received any charge, complaint,
claim, or notice alleging any such interference, infringement,
misappropriation, or violation. To the knowledge of the Company (and
employees with responsibility for Intellectual Property matters), no third
party has interfered with, infringed upon, misappropriated, or otherwise come
into conflict with any Intellectual Property rights of the Company. Except as
set forth in Section (c) of Schedule 2.16, no stockholder, officer or director
of the Company or any other third party owns or has any interest in any
Intellectual Property owned or used by the Company.
(f) Section (f) of Schedule 2.16 identifies all individuals and
other entities who or which materially contributed to the development of the
Intellectual Property. Except as disclosed in Section (f) of Schedule 2.16
9
<PAGE>
each employee and independent consultant of the Company and each other Person
to whom the Company has disclosed any of the Intellectual Property is bound by
a confidentiality agreement which requires such Person to take reasonable
steps to protect the rights of the Company to the Intellectual Property.
2.17 Property and Casualty Insurance. Schedule 2.17 sets forth a true
-------------------------------
and correct list of all insurance policies held by the Company in effect on
the date hereof, including the types and amounts of coverage and the
expiration dates thereof, and a true and complete copy of each such policy has
been delivered to Magellan. Such policies provide for coverage in amounts
deemed by the Company to be adequate in the type of business in which the
Company is engaged, and all premiums due to the date hereof have been paid in
full. To the knowledge of the Company, all of such policies have been issued
by insurance companies that are in good standing with adequate financial
resources to respond to the required coverage, and that are actively engaged
in the insurance business. All claims made against the Company that are
covered by insurance are either being defended by the relevant insurance
company, or are claims as to which the Company has received the assurance of
such insurance company that it will reimburse the Company if such claims are
resolved against the Company.
2.18 Contracts and Agreements: No Defaults. Section (a) of Schedule
-------------------------------------
2.18 sets forth a true and complete list of all contracts and agreements
involving the payment, receipt or use of assets, services, or sales of goods,
to which the Company is a party or by which the Company or its assets are
bound, a true and complete copy of which has been delivered to Magellan.
Except as set forth in Section (a) of Schedule 2.18, the Company is not a
party to any written or oral: (i) lease; (ii) royalty, distribution, agency,
territorial or license agreement; (iii) contract or agreement (for employment
or otherwise) with any past, present or future employee, officer, director,
professional person or firm, independent contractor or advertising firm or
agency that is not terminable at will on notice from the Company without any
payment or penalty whatsoever; (iv) contract or collective bargaining
agreement with any labor union or representative of employees; (v) commitment,
contract or agreement with respect to the repayment of indebtedness of the
Company or guaranteeing the payment or performance of the obligations of
others; (vi) commitment, contract or agreement not made in the ordinary course
of business; and (vii) contract or agreement that would not, by its terms,
continue in full force and effect after the transactions contemplated by this
Agreement or the agreements related thereto without the necessity of obtaining
the consent of such other party. Except as set forth in Section (b) of
Schedule 2.18, the Company has performed all obligations required to be
performed by it and has not received notice of any default and to its
knowledge is not in default under any arrangement, commitment, contract,
agreement, lease, license or other document to which it is a party or by which
it or its assets are bound, and no event or condition that, with the giving of
notice, the lapse of time or both, would become a default has occurred
(including without limitation any failure to pay any amount required by any
such arrangement, commitment, contract, agreement, lease, license or other
document on a timely basis), except for any such default, event or condition
that, individually or in the aggregate, would not be reasonably likely to
result in a Material Adverse Effect. Except as described on Schedule 2.18,
the Company has not made any warranty, guaranty or other similar undertaking
with respect to any of its products or services.
10
<PAGE>
2.19 Purchase Commitments and Orders. Schedule 2.19 sets forth a list
-------------------------------
of all outstanding purchase commitments and orders of the Company that are in
excess of $1,000 or are not in the ordinary and usual course of business.
2.20 Loan Agreements, Debt Instruments and Guarantees. Section (a) of
------------------------------------------------
Schedule 2.20 sets forth a true and complete list of all loan agreements, debt
instruments, guarantees, or any related documents of any nature whatsoever
that are outstanding on the date hereof and to which the Company is a party or
by which it is bound and the Company has delivered a copy of each item listed
on such Schedule to Magellan. Except as set forth in Section (b) of Schedule
2.20, (i) all outstanding liabilities and debts of the Company may be prepaid
in whole or in part at any time without penalty, (ii) all of such liabilities
and debts will continue as liabilities and debts of the Company
notwithstanding the transactions contemplated by this Agreement and the
agreements related thereto without mandatory prepayment, penalty or points,
and (iii) no event or condition has occurred that, with the giving of notice,
the lapse of time or both, would become a default by either party under any
such loan agreement, debt instrument, guaranty, or any related document.
Section (c) of Schedule 2.20 sets forth the principal amount outstanding under
all loan agreements, other debt instruments, guarantees or related documents
of the Company, together with accrued interest thereon.
2.21 Labor Discussions and Troubles. The Company is not currently, nor
------------------------------
during the past 24 months has it been, involved in any labor discussions with
any unit or group seeking to become a bargaining unit for any of its
employees. There are no strikes or other labor troubles now pending or, to
the best knowledge of the Company, threatened-against the Company.
2.22 Claims and Litigation. Except as set forth on Schedule 2.22,
---------------------
there are no Claims pending or, to the knowledge of the Company, threatened
against or affecting the Company, and the Company, after due inquiry of the
executive officers of the Company, does not know of any valid basis for any
such Claims. There are no Claims pending or, to the knowledge of the Company,
threatened against the Stockholders or the Company seeking to prevent or
challenging the transactions contemplated by this Agreement and the agreements
related thereto. The Company is not in default with respect to any order,
writ, judgment, injunction or decree of any court or any governmental
department, commission, board, agency or instrumentality, domestic or foreign.
Except as set forth on Schedule 2.22, there have not been any claims made or
threatened under any warranty or with respect to any products or services sold
by the Company, and to the knowledge of the Company there does not exist any
basis for any such claims.
2.23 Compliance with Laws, Orders, Bylaws, Rules and Regulations.
-----------------------------------------------------------
Except as set forth in Schedule 2.23, the Company has not received notice of
any non-compliance under, and the Company has complied in all material
respects with, all laws, orders, certificates of public convenience and
necessity, tariffs and regulations of any governmental department, commission,
board, agency or instrumentality, domestic or foreign, affecting the Company
or affecting its customers to the extent that the Company is obligated to
comply on behalf of any such customers (including, but not limited to, laws,
orders, and regulations relating to medical products and devices (on both
state and federal level), zoning, building codes, anti-trust, wage and hour,
11
<PAGE>
price guidelines, Food and Drug Administration rules and regulations, the
Occupational Safety and Health Act, hiring, collective bargaining,
Environmental Laws and the payment of withholding and social security taxes).
All permits, licenses and other authorizations and approvals necessary for or
material to the conduct of the business of the Company have been duly obtained
and are in full force and effect. There are no proceedings pending or, to the
knowledge of the Company, threatened that may result in the revocation,
cancellation, suspension or modification of any of such permits, licenses or
other authorizations and approvals.
2.24 Absence of Certain Changes. Except as expressly permitted by this
--------------------------
Agreement, since the Interim Financial Statements Date, the Company has not
(i) mortgaged, pledged or subjected to any Lien any of its assets, tangible or
intangible, (ii) sold or transferred any of its assets or canceled any debts
or claims, except for the sale of inventory and the collection of receivables
in the ordinary course of business, (iii) assigned, subleased, sublicensed,
terminated, or received notice of the termination of any lease or license with
respect to any property (except customer agreement terminations consistent
with good business practices), (iv) suffered any losses (other than ordinary
losses from operations incurred in the ordinary course of business) or waived
any rights of substantial value, (v) made or guaranteed any loans to any
Person, (vi) entered into any transactions other than in the ordinary course
of business, other than this Agreement, (vii) incurred any obligation to pay
commissions or other amounts to any party (except in the ordinary course of
business), (viii) incurred any material liability, obligation or indebtedness,
direct or indirect, absolute or contingent, whether due or to become due, (ix)
canceled, without payment in full, any notes, loans or other obligations
receivable from the Stockholders, any officer, director or employee of the
Company, or any other Person, or (x) declared, made, set aside or paid any
dividend or any distributions or payments on, or any purchase or redemption
of, any class of stock or other equity interest of the Company or any
commitments therefor.
2.25 No Material Adverse Change. Since the Interim Financial
--------------------------
Statements Date there has been no material adverse change in the business,
operations, properties or assets or in the condition, financial or otherwise,
of the Company, as shown on the Interim Balance Sheet other than as expressly
permitted by this Agreement.
2.26 Employees; Employment Practices; Compensation and Vacations.
------------------------------------------------------------
Schedule 2.26 contains a true and complete listing of all employees of the
Company as of the date hereof, their annual salary, date of hire, date of next
review and date of last review. Except as set forth on Schedule 2.26, there
are no vacation pay, bonuses, commissions, sick pay, or other fees or benefits
in respect of work done, earned or due to or expected by any present, former
or prospective employees, not fully paid or accrued on the Company Balance
12
<PAGE>
Sheet. The Company has not received notice of any non-compliance and, to the
knowledge of the Company, the Company is in compliance with the Fair Labor
Standards Act and any similar state, county or local legislation, ordinance or
regulation. Except as set forth on Schedule 2.26, the Company is not
currently involved in any Claim, nor, to the knowledge of the Company, is any
Claim threatened, involving an unfair employment practice, wage and hour
violation, or occupational safety and health violation under any federal,
state, county or local law, including, but not limited to, those arising out
of the Civil Rights Act of 1964 (as amended), the Fair Labor Standards Act, or
the Occupational Safety and Health Act. Except as set forth on Schedule 2.26,
since January 1, 1997, except in the ordinary course of business and
consistent as to timing and amount with past practices, the Company has not
(i) increased the compensation payable or to become payable to or for the
benefit of any of its employees, (ii) provided any of its employees with
increased security or tenure of employment, (iii) increased the amount payable
to any of its employees upon the termination of any such person's employment,
or (iv) increased, augmented or improved benefits granted to or for the
benefit of any of its employees under any bonus, stock option, profit sharing,
pension, retirement, deferred compensation, insurance or other direct or
indirect benefit plan or arrangement. Schedule 2.26 sets forth a description
of each contract or other agreement, including any employment agreement or
stock option agreement, whether written or oral, between the Company and any
person employed by the Company during the past three years, or any present or
future employee of the Company, together with true and complete copies of each
such contract or other agreement (if in writing).
2.27 Employee Benefit Plans. Schedule 2.27 contains a true and
----------------------
complete listing of each Employee Benefit Plan that provides benefits for
employees or former employees of the Company, of which the Company was a "plan
sponsor" under ERISA, to which the Company contributes or has contributed, or
in which the Company participates or has participated. With respect to each
such Employee Benefit Plan, the Company has heretofore delivered to Magellan
true and complete copies of the following documents, where applicable: (i) the
text of the Employee Benefit Plan (including any amendments thereto) and of
any trust or insurance contract maintained in connection therewith, (ii) the
three most recent annual reports (IRS Form 5500 series), together with
required schedules filed with the IRS and any financial statements or opinions
required under ERISA, (iii) the most recent summary plan description and all
modifications, and (iv) the most recent determination letter issued by the
IRS. With respect to each Employee Benefit Plan listed in Schedule 2.27, to
the extent applicable,
(a) Each such Employee Benefit Plan has been maintained and
operated in all material respects in compliance with its terms and with all
applicable provisions of ERISA, the Code and all applicable regulations,
rulings and other authority issued thereunder;
(b) All contributions required by law to have been made under
each such Employee Benefit Plan to any fund or trust established thereunder or
in connection therewith have been made by the due date thereof;
(c) Each such Employee Benefit Plan intended to qualify under
Section 401(a) of the Code is the subject of a favorable unrevoked
determination letter issued by the Internal Revenue Service as to its
qualified status under the Code, which determination letter may still be
relied upon as to such tax qualified status, and no circumstances have
occurred that would adversely affect qualified status of any such Employee
Benefit Plan;
13
<PAGE>
(d) No Employee Benefit Plan is subject to Title IV of ERISA;
(e) None of such Employee Benefit Plans that are "employee
welfare benefit plans" as defined in Section 3(a) of ERISA provides for
continuing benefits or coverage for any participant or beneficiary of a
participant after such participant's termination of employment except as
required by applicable law, including Section 4980B of the Code or Section
6701 of ERISA; and
(f) Neither the Company nor any trade or business (whether or
not incorporated) under common control with the Company within the meaning of
Section 401 of ERISA has, or at any time has had, any obligation to contribute
to any "Multiemployer Plan".
2.28 Notes and Accounts Receivable. All of the notes and accounts
-----------------------------
receivable of the Company are actual and bona fide notes and accounts
receivable, representing obligations for the total dollar amount thereof shown
on the books of the Company (less reserves, if any), that resulted from the
ordinary course of the Company's business, and, other than Permitted Liens,
there are no Liens on any of such notes or accounts receivable. The detailed
agings of the accounts receivable as at the Interim Financial Statements Date
are set forth in Schedule 2.28. All notes and accounts receivable are current
and collectible, net of the respective reserves shown on the Interim Balance
Sheet, and the Company has not taken any action, or made any offer, to
compromise or settle any notes or accounts receivable for less than their full
value, or that would adversely affect the Company's ability to collect the
notes or accounts receivable or give any person the right of set-off with
respect to amounts owing under the notes or accounts receivable except as
disclosed in Schedule 2.28.
2.29 Inventory and Supplies. The supplies of the Company have been
----------------------
acquired in the ordinary course of business, and are in sufficient quantities
to continue operating the Company in accordance with its regular practices,
and there are no Liens on any of such supplies. The supplies of the Company
reflected on the Company Balance Sheet have been valued at the Company's cost
or market value, whichever is lower, in accordance with generally accepted
accounting principles consistently applied, subject to year end audit
adjustments.
2.30 Valuation of Fixed Assets. The valuation of the fixed assets
-------------------------
owned by the Company as shown on the Company Balance Sheet does not in any
case exceed the cost of the such assets to the Company less any previous
write-downs and less depreciation determined in accordance with GAAP, and the
Company has not written up the value of any such fixed assets since January 1,
1997.
2.31 Capital Expenditures. Except as set forth on Schedule 2.31, there
--------------------
are no capital projects or capital expenditures currently committed for or
undertaken by the Company that are not paid for on the date hereof.
2.32 No Bankruptcy Proceedings. There are no bankruptcy, insolvency or
-------------------------
receivership proceedings outstanding against any of the Stockholders or the
Company, and none of the Stockholders or the Company has made any assignment
for the benefit of any creditors and no execution or attachment has been
levied against the Stockholders or the Company on account of any Lien or
judicial process.
14
<PAGE>
2.33 Bank Accounts and Safe Deposit Boxes Powers of Attorney. Schedule
-------------------------------------------------------
2.33 hereto sets forth (i) the names of all banks in which the Company has an
account (including without limitation any trust account) or safe deposit box;
and (ii) the names of all Persons, if any, holding powers of attorney from the
Company, together with photocopies thereof.
2.34 Casualty Losses. Since the Interim Financial Statements Date
---------------
there has not been any material loss, damage or destruction to or of any of
the assets, property or business of the Company, nor have any of such assets,
properties or business of the Company or any Company Subsidiary been affected
as a result of fire, accident or other casualty, war, civil strife or act of
God.
2.35 Threats of Cancellation. The Company has not received notice of
-----------------------
and the Company has no knowledge that any of the Key Employees has made any
threat to the Company to cancel or otherwise terminate his or her relationship
with the Company or that any customer of the Company has made any threat to
cancel or otherwise terminate its relationship with the Company or intends not
to renew an existing contract expiring within six months of the Closing Date
except as disclosed in Schedule 2.35. Except as set forth in Schedule 2.35
and exclusive of market conditions that are outside of the control of the
Company and the effect of the transactions contemplated hereby, there are no
events or circumstances pending or existing, to the knowledge of the Company,
involving the performance or non-performance of services by the Company that
are currently causing, or are expected to result in, the cancellation or
termination of customer agreements by the customers of the Company within
sixty days after the date hereof in numbers that are greater than twenty-five
percent of the average number of customer cancellations or terminations for
each of the twelve full months prior to the date hereof.
2.36 Environmental Compliance. (i) The Company has not received notice
------------------------
of any violation of or investigation relating to any U.S. federal, state or
local environmental or pollution law, regulation, or ordinance with respect to
assets now or previously owned or operated by the Company that has not been
fully and finally resolved; (ii) all permits, license and other authorizations
which are required under any federal, state, provincial and local laws with
respect to pollution or protection of the environment ("Environmental Laws")
relating to assets now owned or operated by the Company, including
Environmental Laws relating to actual or threatened emissions, discharges or
releases of pollutants, contaminants or hazardous or toxic material or wastes
("Pollutants"), have been obtained and are effective, and, with respect to
assets previously owned or operated by the Company, were obtained and were
effective during the time of the Company's operations; (iii) no conditions
exist on, in or about the properties now or previously owned or operated by
the Company or any third-party properties to which any Pollutants generated
by the Company were sent or released that could give rise on the part of the
Company to liability under any Environmental Laws, claims by third parties
under Environmental Laws or under common law or the occurrence of costs to
avoid any such liability or claim and (iv) to the knowledge of the Company all
operators of the Company's assets are in compliance with all terms and
conditions of such Environmental Laws, permits, licenses and authorizations,
and are also in compliance with all other limitations, restrictions,
conditions, standards, prohibitions, requirements, obligations, schedules and
timetables contained in such laws or contained in any regulation, code, plan,
order, decree, judgment, notice or demand letter issued, entered, promulgated
or approved thereunder, relating to the Company's assets.
15
<PAGE>
2.37 Transactions with Affiliates. Schedule 2.37 sets forth a true and
----------------------------
complete list of all existing contracts, agreements or arrangements of any
nature whatsoever, whether written or oral, between the Company and any holder
of any class of stock or other equity interest in the Company, including the
Stockholders and the holders of any options or warrants (or any immediate
family member of such holder, or any other Person in which such holder owns a
controlling equity interest), including without limitation any employment
agreement or other compensation or reimbursement arrangement, any loan or
guarantee, and any purchase or sale agreement and a copy of each such written
contract, agreement or arrangement and a summary of each such oral contract,
agreement or arrangement has been provided to Magellan.
2.38 Disclosure. None of this Agreement, the agreements related to
----------
this Agreement, the financial statements referred to in Section 2.8 or any
Schedule, Exhibit, agreement, certificate or other document attached hereto or
thereto or delivered in accordance with the terms hereof or thereof contains
any untrue statement of a material fact or omits any statement of a material
fact necessary in order to make the statements contained herein or therein not
misleading.
2.39 Brokers' and Finders' Fees. Except as set forth on Schedule 2.39,
--------------------------
neither the Company nor any Stockholder or officer or director of the Company
has taken any action or entered into any agreement relative to this Agreement
and the transactions contemplated hereby which would give rise to any claim
against the Company, Magellan or ProHealth for a brokerage commission or
finder's fee.
2.40 Representations and Warranties of Each Stockholder. Each
--------------------------------------------------
Stockholder represents and warrants to Magellan and ProHealth, individually as
to such Stockholder and not with respect to any other Stockholder, that the
following statements are, as of the date hereof and will be as of the Closing
Date, true and correct:
(a) Stockholder Investment Status. Such Stockholder is (i) an
-----------------------------
"accredited investor" as defined in Rule 501 of Regulation D promulgated under
the Securities Act or (ii) has such knowledge and experience, either
individually or with its purchaser representative (as defined in such Rule
501), in financial and business matters that such Stockholder is capable of
evaluating the merits and risks of acquiring the Magellan Stock as
contemplated by this Agreement. Such Stockholder is receiving the Magellan
Common Stock for his own account and not as a fiduciary for any other person
and for investment purposes only and not with a view to or for the transfer,
assignment, resale, or distribution thereof, in whole or in part. Such
Stockholder understands that (A) the Magellan Stock that he, she or it will
receive pursuant to this Agreement has not been registered under the
Securities Act, (B) such Magellan Stock cannot be sold or otherwise disposed
of unless and until such Magellan Stock is registered under the Securities Act
or an exemption from registration is available. Such Stockholder has received
copies of the due diligence items provided by Magellan to the Company. Such
Stockholder has been provided with a copy of this Agreement and schedules plus
Magellan's reports filed with the SEC on Forms 10 KSB and 10 QSB for the year
ending December 31, 1996 and the six months ending June 30, 1997,
respectively, Magellan's Reports to Shareholders and press releases issued
since January 1, 1997, and Magellan's Information Statement provided to
16
<PAGE>
Magellan's shareholders in connection with the Special Meeting of Magellan's
Shareholders on October 27, 1997. Such Stockholder has had an opportunity to
ask questions and receive answers concerning the terms and conditions of the
transactions contemplated hereby and to obtain any additional information that
Magellan possesses or can acquire without unreasonable effort or expense that
is necessary to verify the accuracy of the information furnished to the
Company. Such Stockholder has been represented by such legal and tax counsel
and other advisors, each of whom has been personally selected by such
Stockholders, as such Stockholder has found necessary to consult concerning
this transaction, and such representation has included an examination of
applicable documents, and an analysis of all tax, financial, and securities
law aspects.
(b) Ownership of Stock. Such Stockholder owns of record and
------------------
beneficially the number of shares of the Company Stock indicated opposite such
Stockholders name in Schedule 2.6 hereto, with full right and authority to
transfer such shares hereunder, and upon delivery of such shares hereunder,
Magellan will receive good title thereto, free and clear of all mortgages,
pledges or security interests and not subject to any agreements or
understandings among any Persons with respect to the voting or transfer of
such shares. Upon the transfer, assignment and delivery to Magellan of the
Company Stock owned by such Stockholder in exchange for the issuance of
Magellan Stock to such Stockholder at the Closing, as provided for in this
Agreement, Magellan will acquire good and valid title to the Company Stock
held by such Stockholder, free and clear of any Lien.
(c) Residence and Domicile. Such Stockholder is a resident of,
----------------------
and domiciled in, the State indicated on Exhibit B, as being the residence of
such Stockholder.
(d) Restriction of Transfer of Shares of Magellan Stock. Each of
---------------------------------------------------
the Stockholders hereby acknowledges that the Magellan Stock acquired pursuant
to this Agreement may not be sold, transferred, or otherwise disposed of
without registration under the Securities Act or an exemption therefrom, and
that in the absence of an effective registration statement covering the
acquired Magellan Stock or an available exemption from registration under the
Securities Act, the acquired Magellan Stock must be held indefinitely. Each
Stockholder agrees that in no event will it make a transfer or disposition of
any of the Magellan Stock acquired pursuant to this Agreement unless and until
(i) such Stockholder shall have notified Magellan of the proposed disposition;
and (ii) if requested by the Magellan, such Stockholder shall have furnished
to Magellan at the expense of such Stockholder or its transferee, an opinion
of counsel reasonably satisfactory to Magellan to the effect that such
transfer may be made without registration under the Securities Act. Each
Stockholder acknowledges that Magellan is under no obligation to register the
shares of Magellan Stock to be acquired by the Stockholders under the
Securities Act. Such Stockholder has adequate means of providing for his or
her current needs and possible personal contingencies and has no need now, and
anticipates no need in the foreseeable future, to sell shares of the Magellan
Stock which the undersigned will receive. Such Stockholder is able to bear
the economic risks of this investment, and consequently, without limiting the
generality of the foregoing, is able to hold the shares of Magellan Stock to
be received in the Merger for an indefinite period of time and has a
sufficient net worth to sustain a loss of the entire investment, in the event
such loss should occur.
17
<PAGE>
(e) Certificate Legend. All certificates for shares of Magellan
------------------
Stock delivered under the terms of this Agreement shall bear the following
legend:
THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933 OR THE SECURITIES ACT OF ANY STATE AND THUS
MAY NOT BE TRANSFERRED OR HYPOTHECATED UNLESS
REGISTERED UNDER THE SECURITIES ACT OF 1933 AND
ANY APPLICABLE STATE SECURITIES LAW OR UNLESS AN
EXEMPTION FROM REGISTRATION IS AVAILABLE UNDER
BOTH THE SECURITIES ACT OF 1933 AND ANY
APPLICABLE STATE SECURITIES LAW."
(f) Brokers or Finders Fees. No Stockholder or any of such
-----------------------
Stockholder's agents have incurred any obligation or liability, contingent or
otherwise, for brokerage or finder's fees or agents' commissions or other
similar payment in connection with this Agreement.
(g) Execution, Delivery and Enforceability of Agreement; No
-------------------------------------------------------
Violation. This Agreement has been, and when executed and delivered the
- ---------
agreements related hereto will have been, duly executed and delivered by such
Stockholder and this Agreement does, and the agreements related hereto will,
constitute the legal, valid and binding obligation of such Stockholder
enforceable against such Stockholder in accordance with its terms, except as
such enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting the enforcement of
creditors' rights generally. Such Stockholder has all requisite power and
authority and full legal capacity to execute and deliver this Agreement and
the agreements related hereto and to perform its obligations hereunder and
thereunder, including, without limitation, all right, power, capacity and
authority to assign, deliver and transfer the Company Stock as provided by
this Agreement.
(h) Transfer of Magellan Stock. Such Stockholders have no plan,
--------------------------
intention, or arrangement to dispose of an amount of the Magellan Stock to be
received in a manner that would violate the continuity of interests
requirements set forth in Treasury Regulation Section 1.368-1.
ARTICLE 3
REPRESENTATIONS AND WARRANTIES OF MAGELLAN
Magellan represents and warrants to each of the Stockholders that:
3.1 Organization and Standing.
-------------------------
(a) Magellan (i) is a corporation duly organized, validly
existing and in good standing under the laws of the state of State of Utah and
has all necessary power and authority to own, lease or license its property
and to conduct its business as now conducted, and (ii) is duly qualified or
licensed to do business in all jurisdictions where the nature of its business
or properties owned or leased by it make such qualification or licensing
18
<PAGE>
necessary, except where the failure to so qualify would have no Material
Adverse Effect on Magellan. ProHealth (i) is a wholly-owned subsidiary of
Magellan, and (ii) is a corporation duly organized, validly existing and in
good standing under the laws of the State of Utah and has all necessary power
and authority to own, lease or license its property and to conduct its
business as now conducted.
(b) Each of the Magellan Subsidiaries is a corporation duly
organized and validly existing and in good standing under the laws of the
state of its incorporation or formation. Each Magellan Subsidiary (i) has all
necessary power and authority to own, lease or license its property and to
conduct its business as now conducted, and (ii) is duly qualified or licensed
to do business in all jurisdictions where the nature of its business or the
properties owned or leased by it make such qualification or licensing
necessary, except where the failure to so qualify would not have a Material
Adverse Effect on Magellan and the Magellan Subsidiaries, taken as a whole.
3.2 Authorization: Enforceability. Each of Magellan and ProHealth has
-----------------------------
the corporate authority to execute and deliver this Agreement and the
agreements related thereto, to perform its obligations hereunder and
thereunder and to consummate the transactions contemplated hereby and thereby.
Such execution, delivery and performance have been duly authorized by the
Board of Directors of each of Magellan and ProHealth, and all other necessary
corporate action of Magellan and ProHealth has been taken. This Agreement has
been, and when delivered the agreements related hereto will have been, duly
executed and delivered by each of Magellan and ProHealth. This Agreement, and
when executed and delivered each of the agreements related hereto, constitutes
the legal, valid and binding obligation of each of Magellan and ProHealth
enforceable against it in accordance with their respective terms, except as
such enforceability may be limited to applicable bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting the enforcement of
creditors rights generally.
3.3 Consents. Except as set forth in Schedule 3.3, no consent under
--------
any indenture, contract, instrument or other agreement to which either
Magellan or ProHealth or any Magellan Subsidiary is a party, is required
thereunder to be obtained in connection with the execution, delivery and
performance by either Magellan or ProHealth of this Agreement or the
agreements related thereto. Except as set forth in Schedule 3.3, there are no
consents, approvals or authorizations, declarations, filings or registrations
with, or notices to, any governmental or regulatory authority required to be
made or obtained by Magellan or ProHealth or any Magellan Subsidiary in
connection with the execution and delivery of this Agreement and the
agreements related hereto and the performance of the transactions contemplated
hereby and thereby, except where the failure to obtain such consent, approval
or authorization or make such declaration, filing or registration, or give
such notice, would not have a Material Adverse Effect on Magellan and the
Magellan Subsidiaries, taken as a whole.
3.4 Non-Contravention. Except as set forth on Schedule 3.4, the
-----------------
execution, delivery and performance of this Agreement and the agreements
related hereto by Magellan and ProHealth, as the case may be, will not breach
or violate any provision of, or cause any event by which a right of
termination or acceleration or Lien on any of Magellan's, ProHealth's or any
Magellan Subsidiary's properties would arise under: (i) any statute or
19
<PAGE>
regulation or any order of any court or other agency of government or any
judgment, award or decree; (ii) the articles of incorporation or bylaws of
either Magellan and ProHealth, or (iii) any indenture, contract, instrument or
other agreement by which Magellan, ProHealth or any Magellan Subsidiary is
bound.
3.5 SEC Documents. Magellan has made available to the Company a true
-------------
and complete copy of each report, schedule, registration statement and
definitive proxy statement filed by Magellan with the SEC since January 1,
1996 and prior to the date of this Agreement (the "Magellan SEC Documents")
which are all the documents that Magellan was required to file with the SEC
since such date. As of their respective dates, the Magellan SEC Documents
complied in all material respects with the requirements of the Securities Act
or the Exchange Act, as the case may be, and the rules and regulations of the
SEC thereunder applicable to such Magellan SEC Documents, and none of the
Magellan SEC Documents contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary to
make the statements therein, in light of the circumstances under which they
were made, not misleading. As of their respective dates, the financial
statements of Magellan included in the Magellan SEC Documents complied as to
form in all material respects with the published rules and regulations of the
SEC with respect thereto, were prepared in accordance with GAAP, during the
periods involved (except as may be indicated in the notes thereto or, in the
case of the unaudited statements, as permitted by Rule 10-01 of Regulation S-X
of the SEC) and fairly presented in accordance with applicable requirements of
GAAP (subject, in the case of the unaudited statements, to normal, recurring
adjustments, none of which are material) the consolidated financial position
of Magellan and its consolidated Magellan Subsidiaries as of their respective
dates and the consolidated results of operations and the consolidated cash
flows of Magellan and its consolidated Magellan Subsidiaries for the periods
presented therein.
3.6 Capital Stock. The issuance and delivery by Magellan of the
-------------
Magellan Stock in connection with this Agreement have been duly approved and
validly authorized by all necessary corporate action on part of Magellan and
such Magellan Stock, when issued in accordance with the terms of this
Agreement, will be validly issued, fully paid and nonassessable.
3.7 Brokers' and Finders' Fees. Neither Magellan, ProHealth or any
--------------------------
Magellan Subsidiary or any officer or director of Magellan, ProHealth or any
Magellan Subsidiary has taken any action or entered into any agreement
relative to this Agreement or the transactions contemplated hereby which would
give rise to any claim against Magellan, ProHealth or any Magellan Subsidiary
or the Company or any Stockholder for a brokerage commission or finders' fee.
3.8 Claims and Litigation. There are no Claims pending or, to the
---------------------
knowledge of Magellan, threatened against Magellan seeking to prevent or to
challenge the transactions contemplated by this Agreement and the agreements
related hereto.
20
<PAGE>
ARTICLE 4
COVENANTS OF THE COMPANY AND THE STOCKHOLDERS
4.1 Ongoing Management of the Company. Except as expressly
---------------------------------
contemplated by this Agreement or otherwise agreed to in writing by Magellan,
during the period from the date hereof to the Closing Date, (i) the Company
will continue to operate its respective business in the ordinary course, in
accordance with usual procedures and past practices, and (ii) the Company will
use commercially reasonable efforts: (A) to preserve its business organization
intact, (B) to keep available the services of its present officers and
employees, and (C) to preserve for Magellan the present relationships between
the Company and their respective vendors, dealer groups and other customers,
banks and other third parties having business relations with it. Without
limiting the generality of the foregoing, and except as otherwise expressly
provided in or contemplated by this Agreement, between the date hereof and the
Closing Date, the Company will not, without the prior written consent of
Magellan:
(a) amend its Articles of Incorporation or Bylaws;
(b) issue, sell, grant, award, pledge or dispose of (other than
in connection with the proper exercise of an outstanding option) any shares of
its capital stock or other equity interests, any options, warrants or rights
of any kind to acquire any shares of its capital stock or other equity
interests or any securities that are convertible into or exchangeable for any
shares of its capital stock or other equity interests;
(c) split, combine or reclassify any shares of its capital stock
or other equity interests, declare, set aside or pay any dividend or other
distribution (whether in cash, stock or property or any combination thereof)
in respect of any shares of its capital stock or other equity interests, or
redeem or otherwise acquire any shares of its capital stock or other equity
interests;
(d) provide for the acceleration of vesting of any Company
Options, whether pursuant to the Company Option Agreements (except in
accordance with their terms), or otherwise;
(e) create, incur (other than in the ordinary course of business
under existing credit facilities), assume, become or be liable for, directly,
indirectly or contingently, in any manner with respect to any indebtedness for
borrowed money;
(f) create, incur, or grant a security interest in or lien upon,
pledge, mortgage, or otherwise encumber any of its properties or assets or
allow or suffer any security interest, lien or other encumbrance to attach to
any of its properties;
(g) sell any of its assets or properties, other than in the
ordinary course of business, or purchase a material equity interest in, or
material portion of the assets of, or merge with or into or enter into any
business combination involving, any other company or entity;
(h) make capital expenditures other than those set forth on
Schedule 2.31 or investments or commitments therefor) other than in the
ordinary course of business and in amounts less than $1,000 in the aggregate;
21
<PAGE>
(i) settle or compromise any litigation involving the payment
of, or an agreement to pay over time, an amount, in cash, notes or other
property, in excess of $1,000 in the aggregate.
(j) make any election for Tax purposes;
(k) enter into, or amend or terminate, any material agreement,
contract or other instrument, or waive, release or cancel any debts, claims or
rights (except for new contracts, or amendments or terminations of existing
contracts, with customers, consistent in each instance with the ordinary
course of business and good business practices);
(l) purchase, invest in or otherwise acquire or hold securities,
including, without limitation, capital stock and evidences of indebtedness of,
or make loans or advances to, or enter into any arrangement for the purpose of
providing funds or credit to, any other person;
(m) sell, assign, discount or dispose in any way of any accounts
receivable, promissory notes or trade acceptances held by the Company, with or
without recourse, except for collection (including endorsements) in the
ordinary course of business;
(n) enter into any transaction, including, without limitation,
the purchase, sale or exchange of property or assets or the rendering or
accepting of any service with or to any Affiliate of the Company;
(o) enter into any employment or consulting agreement with any
employee or consultant or increase the compensation or benefits of any
executive of the Company; or
(p) agree, whether in writing or otherwise, to do any of the
foregoing.
4.2 Access to Information. From the date hereof to the Closing, the
---------------------
Company will afford Magellan and its counsel, accountants and other
representatives complete access at all reasonable times to the officers,
employees, properties, contracts, books and records of the Company, and the
Company will promptly furnish to Magellan all financial, operating, tax and
other data and information as Magellan may reasonably request concerning the
business, operations, properties and personnel of the Company.
4.3 Notification of Certain Matters. The Stockholders and the Company
-------------------------------
will give prompt notice to Magellan of (i) the occurrence, or failure to
occur, of any event which occurrence or failure would be likely to cause any
representation or warranty of the Stockholders or the Company contained in
this Agreement to be untrue or inaccurate at any time from the date hereof to
the Closing, and (ii) any failure of the Stockholders or the Company to comply
with or satisfy any covenant, condition or agreement to be complied with or
satisfied by the Stockholders or the Company hereunder.
4.4 Tax Reporting of the Merger. Each of the Stockholders covenants
---------------------------
and agrees to prepare and file all Returns to which the status of the Merger
as a reorganization under Section 368 of the Code is relevant in a manner
consistent with the Merger constituting such reorganization.
22
<PAGE>
4.5 Reasonable Efforts. The Company and each of the Stockholders will
------------------
use such party's reasonable efforts to take or cause to be taken all actions,
and to do or cause to be done all other things necessary, proper and advisable
in order to consummate and make effective the transactions contemplated by
this Agreement and the Escrow Agreement (including satisfaction, but not
waiver, of the closing conditions set forth in Article 7 hereto).
4.6 Required Approvals. As promptly as practicable after the date of
------------------
this Agreement, the Company and the Stockholders will make all filings
required by any applicable federal, state or local law, regulations or
ordinance to be made by them in order to consummate the merger. Between the
date of this Agreement and the Closing Date, the Company and the Stockholders
will, and will cause the Company to cooperate with Magellan with respect to
any filings that Magellan elects to make or is required to make pursuant to
any federal, state or local law, regulation or ordinance.
4.7 No Negotiation. Until such time, if any, as this Agreement is
--------------
terminated pursuant to Article 8, neither the Company, nor the Stockholders,
nor any officers, director, employee or representative of the Company or
Stockholder, will, directly or indirectly, solicit, initiate or encourage any
inquiries or proposals from, discuss or negotiate with, provide any non-public
information to, or consider the merits of any unsolicited inquiries or
proposals from any Person, other than Magellan, relating to any transaction
involving the sale of the business or assets of the Company, or any of the
capital stock of the Company, or any merger, consolidating business
combination or similar transaction.
ARTICLE 5
COVENANTS OF MAGELLAN
5.1 Notification of Certain Matters. Magellan will give prompt notice
-------------------------------
to each of the Stockholders and the Company of (i) the occurrence, or failure
to occur, of any event which occurrence or failure would be likely to cause
any representation or warranty of Magellan contained in this Agreement to be
untrue or inaccurate at any time from the date hereof to the Closing and (ii)
any failure of comply with or satisfy any covenant, condition or agreement to
be complied with or satisfied by it hereunder.
5.2 Tax Reporting of the Merger. Magellan covenants and agrees to
---------------------------
prepare and file all Returns to which the status of the Merger as a
reorganization under Section 368 of the Code is relevant in a manner
consistent with the Merger constituting such reorganization.
5.3 Reasonable Efforts. Magellan will use its reasonable efforts to
------------------
take or cause to be taken all actions, and to do or cause to be done all other
things necessary, proper or advisable in order to consummate and make
effective the transactions contemplated by this Agreement (including
satisfaction, but not waiver, of the closing conditions set forth in Article 6
hereto).
23
<PAGE>
ARTICLE 6
CONDITIONS TO THE OBLIGATIONS OF MAGELLAN
The obligations of Magellan and ProHealth to complete the transactions
contemplated by this Agreement on the Closing Date will be subject to the
satisfaction or waiver by Magellan of the conditions precedent set forth below
in this Article 6.
6.1 Performance. On or before the Closing Date, the Stockholders and
-----------
the Company shall have complied with and performed the agreements and
satisfied the conditions to be complied with, performed and satisfied, as the
case may be, by them pursuant to this Agreement on or before the Closing Date.
6.2 Representations and Warranties True and Correct. The
-----------------------------------------------
representations and warranties of the Stockholders, and the Company contained
in this Agreement shall be true and correct on the Closing Date as if made on
and as of the Closing Date.
6.3 Officer's Certificate. Magellan shall have received a
---------------------
certificate from each Stockholder and the Company certifying that the
conditions set forth in Sections 6.1 and 6.2 have been satisfied and complied
with.
6.4 Good Standing Certificate. Magellan shall have received a
-------------------------
certificate from the Division of Corporations and Commercial Code (and all
other jurisdictions in which the Company conducts business) certifying that
the Company is in good standing in such state and has paid all applicable
taxes.
6.5 No Litigation. No court action or proceeding shall have been
-------------
instituted to restrain or prohibit the transactions contemplated by this
Agreement and the agreements related hereto and at the Closing Date there
shall be no Claims, whether or not fully covered by insurance, that (i) would
have a substantial probability of restraining or prohibiting or creating
damages in connection with the transactions contemplated by this Agreement and
the agreements related thereto or (ii) could result in any material adverse
change in the business, operations, properties or assets or in the condition,
financial or otherwise, of the Company. Magellan shall have received a
certificate to that effect dated the Closing Date and executed by each of the
Stockholders and the President of the Company.
6.6 Government Approvals. All government filings, notices,
--------------------
applications, consents and approvals necessary to permit the consummation of
the transactions contemplated by this Agreement and the agreements related
thereto or necessary to allow the Company to continue to conduct its business
as conducted prior to the Merger after the Merger shall have been made or
received, as the case may be.
6.7 No Material Adverse Change. Prior to the Closing Date, there
--------------------------
shall have been no material adverse change in the business, operations,
properties or assets or in the condition, financial or otherwise, of the
Company from the Interim Financial Statement Date up to the Effective Time and
Magellan shall have received a certificate to that effect dated the Closing
Date and executed by each of the Stockholders and the Company.
24
<PAGE>
6.8 Consents. A consent or waiver with respect to each of the items
--------
listed in Schedule 2.4 shall have been obtained in writing by the Company and
a consent or waiver with respect to each of the items listed on Schedule 3.4
shall have been obtained by Magellan and ProHealth.
6.9 Proceedings. All proceedings to be taken in connection with the
-----------
transactions contemplated by this Agreement and all documents incident thereto
will be reasonably satisfactory in form and substance to Magellan and its
counsel, and Magellan shall have received copies of all such documents and
other evidence or their counsel may reasonably request in order to establish
the consummation of such transactions and the taking of all proceedings in
connection therewith.
6.10 Delivery of Employment Agreements. Each of the Key Employees shall
---------------------------------
have executed and delivered the Employment Agreements in the form attached
hereto as Exhibit C, and such Employment Agreements shall be in full force and
effect.
6.11 Delivery of Unaudited Financial Statements. Magellan shall have
------------------------------------------
received (i) an unaudited balance sheet of the Company as at the last full
month ending prior to the Closing Date, and (ii) an unaudited financial
statement of income and retained earnings of the Company setting forth revenue
and expenses for each complete calendar month from the Interim Financial
Statements Date through the last full month ending prior to the Closing Date,
which balance sheet and statement of income and retained earnings will in each
case be certified by the Company's president and chief financial officer on
the same terms and the certificates given pursuant to Section 2.8(b). There
shall have been no material changes to such balance sheet from the Company
Balance Sheet or the Company's financial position as of such date.
6.12 Delivery of Escrow Agreement. The Stockholders and the Escrow
----------------------------
Agent shall have executed and delivered the Escrow Agreement.
6.13 Customer Cancellations. There shall have been no material
----------------------
cancellations of contracts or relationships by customers, clients, or agents
of the Company after the date hereof other than in the ordinary course of
business consistent with past experience.
6.14 Client Agreements. Magellan shall have received copies of each of
-----------------
the agreements between the Company and each of its clients, agents or
customers and such agreements shall be in form and substance reasonably
satisfactory to Magellan.
6.15 Legal Opinion. Magellan shall have received the opinion of Dredge
-------------
& Lallatin, L.C., counsel for the Company, in form and substance reasonably
satisfactory to Magellan covering such matters as Magellan shall reasonably
require.
6.16 Liens. The Liens listed in Section (ii) of Schedule 1.1 shall
-----
be reasonably acceptable to Magellan.
25
<PAGE>
6.17 Dissenters Rights. No Stockholder shall have elected dissenters
-----------------
rights.
6.18 Due Diligence. Magellan shall have completed an investigation
-------------
which shows that the financial condition, the conduct of the Company and
operations of its business, is satisfactory to Magellan, in its sole
discretion.
ARTICLE 7
CONDITIONS TO THE STOCKHOLDER'S OBLIGATIONS
The obligations of the Stockholders and the Company to consummate the
transactions contemplated by this Agreement on the Closing Date will be
subject to the satisfaction (or waiver by each of the Stockholders and the
Company) of the conditions set forth below.
7.1 Performance. On or before the Closing Date, Magellan shall have
-----------
complied with and duly performed the agreements, covenants, terms and
conditions to be complied with and performed by it pursuant to this Agreement
on or before the Closing Date.
7.2 Representations and Warranties True and Correct. The
-----------------------------------------------
representations and warranties of Magellan contained in this Agreement shall
be true and correct on the Closing Date with the same force and effect as
though such representations and warranties had been made on and as of the
Closing Date.
7.3 Officer's Certificate. The Stockholders will have received a
---------------------
certificate dated the Closing Date and executed by a corporate officer of
Magellan to the effect that the conditions set forth in Section 7.1 and 7.2
have been satisfied and complied with.
7.4 No Litigation. No court action or proceeding will have been
-------------
instituted to restrain or prohibit the transactions contemplated by this
Agreement and the agreements related thereto and at the Closing Date there
will be no Claims, whether or not fully covered by insurance, that (i) would
have a substantial probability of restraining or prohibiting or creating
damages in connection with the transactions contemplated by this Agreement and
the agreements related thereto, or (ii) could result in any material adverse
change in the business, operations, properties or assets or in the condition,
financial or otherwise, of Magellan and the Magellan Subsidiaries, taken as a
whole, and the Stockholders will have received a certificate to that effect
dated the Closing Date and executed by a corporate officer of Magellan.
7.5 Government Approvals. All, government filings, notices, consents
--------------------
and approvals necessary to permit the consummation of the transactions
contemplated by this Agreement will have been made or received, as the case
may be.
7.6 Proceeding. All proceedings to be taken in connection with the
----------
transactions contemplated by this Agreement and all documents incident thereto
will be reasonably satisfactory in form and substance to the Stockholders and
26
<PAGE>
their counsel, and the Stockholders will have received copies of all such
documents and other evidence as they or their counsel may reasonably request
in order to establish the consummation of such transactions and the taking of
all proceedings in connection therewith.
7.7 Delivery of Escrow Agreement. Magellan and the Escrow Agent will
----------------------------
have executed and delivered the Escrow Agreement in substantially the form
attached hereto as Exhibit D with such changes as shall be agreed to by
Magellan and the Stockholders.
7.8 Delivery of Royalty Agreements. Magellan and the Company shall
------------------------------
have executed and delivered to each of the Stockholders the Royalty Agreements
substantially in the form attached hereto as Exhibit E with such changes as
shall be agreed to by Magellan and the Stockholders.
ARTICLE 8
TERMINATION, AMENDMENT AND WAIVER
8.1 Termination. This Agreement may be terminated at any time prior
-----------
to the Closing Date in accordance with the provisions of this Section 8.1 by
mutual consent of Magellan and the Company. If the transactions contemplated
hereby shall not have been consummated on or before October 31, 1997 (or any
extensions thereof, as agreed to by the parties in writing), either of the
Company or Magellan (i) acting jointly or (ii) acting individually may
terminate this Agreement at any time thereafter upon at least five (5)
Business Days prior notice to the other parties hereto in accordance with the
provisions of Section 10.2.
ARTICLE 9
INDEMNIFICATION
9.1 Indemnity.
---------
(a) Each of the Stockholders agrees, jointly and severally, to
indemnify, defend and hold harmless each Magellan Indemnified Party from and
against, and pay or reimburse each Magellan Indemnified Party for, any Loss,
whether or not resulting from any third party claim, incurred or suffered by
such Magellan Indemnified Party with respect to or in connection with the
following (one or more of which may apply to any such Loss):
(i) any breach of or any failure to be true and correct in
all material respects as of the date of this Agreement and as of the
Closing Date of any representation or warranty made in or pursuant to
this Agreement or the Schedules or Exhibits hereto or in any other
agreements, certificates or documents delivered in connection with the
Closing pursuant hereto or thereto by any of the Stockholders or the
Company; or
(ii) any breach or nonfulfillment of any covenant or
obligation of any of the Stockholders or the Company under this
Agreement or under any other agreements, certificates or documents
delivered in connection with the Closing pursuant hereto or thereto by
any of the Stockholders or the Company.
27
<PAGE>
(b) Magellan will indemnify, defend and hold each of the
Stockholders harmless from and against, and pay and reimburse each of the
Stockholders for, any Loss, whether or not resulting from any third party
claim, incurred or suffered by any of the Stockholders with respect to or in
connection with:
(i) any breach or any failure to be true and correct in
all material respects as of the date of this Agreement and as of the
Closing Date of any representation or warranty made in or pursuant to
this Agreement or the Schedules or Exhibits hereto or in any other
agreements, certificates or documents delivered in connection with the
Closing pursuant hereto or thereto by Magellan or any Magellan
Subsidiary; or
(ii) any breach or nonfulfillment of any covenant or
obligation of Magellan under this Agreement or under any other
agreements, certificates or documents delivered in connection with the
Closing pursuant hereto or thereto by Magellan.
9.2 Indemnification Procedure.
(a) Promptly after the Indemnified Party learns of any event or
circumstance, including, without limitation, any claim by a third party
described in Section 9.2, that, in the judgment of the Indemnified Party, may
give rise to indemnification hereunder, the Indemnified Party will deliver to
the Indemnifying Party and to the Escrow Agent (if the Indemnified Party is a
Magellan Indemnified Party) a certificate (the "Certificate"), which
Certificate will:
(i) state that the Indemnified Party has incurred or
properly accrued Losses, or anticipates that it will incur Losses for
which such Indemnified Party is entitled to indemnification pursuant to
this Agreement, and the actual or estimated amount of the Loss or Losses
incurred or accrued; and
(ii) specify in reasonable detail each individual item of
Loss included in the amount so stated, the date such item was incurred
or properly accrued, or the basis for any anticipated Loss or Losses and
the nature of the misrepresentation, breach of warranty or breach of
covenant or claim to which each such item is related and the computation
of the amount to which such Indemnified Party claims to be entitled
hereunder,
provided, however, that any failure or delay by the Indemnified Party in
delivering a Certificate to the Indemnifying Party will not affect the
Indemnified Party's right to indemnification under this Article 9, except to
the extent that the Indemnifying Party is able to establish its damages
resulting directly from such failure or delay.
(b) In case the Indemnifying Party objects to the
indemnification of an Indemnified Party in respect of any claim described in
any Certificate, the Indemnifying Party will, within ten (10) Business Days
after receipt by the Indemnifying Party of such Certificate, deliver to the
Indemnified Party a written notice to such effect and the Indemnifying Party
and the Indemnified Party will, within the thirty-day period beginning on the
date of receipt by the Indemnified Party of such written objection, attempt in
good faith to agree upon the rights of the respective parties with respect to
28
<PAGE>
each of such claims to which the Indemnifying Party will have so objected. In
the event such claim is in respect of a third-party claim against the
Indemnified Party, the Indemnifying Party will take such actions as are
required pursuant to Section 9.2(c), provided that the Indemnifying Party's
objection against his, her or its liability for indemnification will remain
subject to determination under this Section 9.2(b). If the Indemnified Party
and the Indemnifying Party succeed in reaching agreement on their respective
rights with respect to any of such claims, the Indemnified Party and the
Indemnifying Party will promptly prepare and sign a memorandum setting forth
such agreement. Should the Indemnified Party and the Indemnifying Party be
unable to agree as to any particular item or items or amount or amounts, then
the Indemnified Party and the Indemnifying Party will submit such dispute to a
court of competent jurisdiction.
(c) Promptly after the assertion by any third party of any claim
against any Indemnified Party that, in the judgment of such Indemnified Party,
may result in the incurrence by such Indemnified Party of Losses for which
such Indemnified Party would be entitled to indemnification pursuant to this
Agreement, such Indemnified Party will deliver a Certificate in accordance
with Section 9.2(a) and the Indemnifying Party may, at its option, assume the
defense of the Indemnified Party against such claim (including the employment
of counsel, who will be reasonably satisfactory to such Indemnified Party, and
the payment of expenses). Until the Indemnifying Party will have so assumed
the defense of the Indemnified Party against such claim following the delivery
of such Certificate, the Indemnified Party may, but will not be obligated to,
undertake the defense, compromise or settlement of such claim on behalf of and
for the account and risk of the Indemnifying Party, and if such Indemnified
Party is entitled to indemnification under this Article 9, all legal or other
expenses reasonably incurred by the Indemnified Party will be borne by the
Indemnifying Party. Any Indemnified Party will have the right to employ
separate counsel in any such action or claim by a third party and to
participate in the defense thereof, but the fees and expenses of such counsel
will not be at the expense of the Indemnifying Party unless (i) the
Indemnifying Party will have failed, within ten Business Days after receipt of
a Certificate in respect of such claim, to assume the defenses of such claim
or to notify the Indemnified Party in writing that it will assume the defense
of such claim, (ii) the employment of such counsel has been specifically
authorized in writing by the Indemnifying Party, which authorization will not
be unreasonably withheld, or (iii) the named parties to any such action
(including any impleaded par-ties) include both such Indemnified Party and the
Indemnifying Party and such Indemnified Party will have been advised in
writing by such counsel that there may be one or more legal defenses available
to either party and that the assertion (or nonassertion) by the Indemnifying
Party of any of such defenses will be adverse to the interests of the
Indemnified Party. No Indemnifying Party will be liable to indemnify any
Indemnified Party for any settlement of any such action or claim effected
without the consent of the Indemnifying Party unless the Indemnifying Party
fails to assume the defense of such claims after receipt of notice of such
third party claim, but if settled with the consent of the Indemnifying Party
or if settled without the consent of the Indemnifying Party if the
Indemnifying Party fails to assume the defense thereof, or if there be final
judgment for the plaintiff in any such action, the Indemnifying Party will
indemnify and hold harmless each Indemnified Party from and against any Loss
or Losses by reason of such settlement or judgment. After any such claim has
been filed or initiated, each party will make available to the other and its
attorneys and accountants all pertinent information under its control relating
to such claim that is not confidential or proprietary in nature or that is
made available under the terms of a confidentiality agreement or is delivered
29
<PAGE>
or obtained under appropriate protective orders satisfactory to such party and
the parties agree to render to each other such assistance as they may
reasonably require of each other in order to facilitate the proper and
adequate defense of any such claim.
(d) Within thirty (30) Business Days of the determination of the
amount of any (i) claims for Losses specified in any Certificate to which an
Indemnified Party shall not object in writing within ten Business Days of
receipt of such Certificate, (ii) claims for Losses covered by a memorandum of
agreement of the nature described in Section 9.2(b), (iii) claims for Losses
the validity and amount of which have been the subject of judicial
determination as described in such Section 9.2(b) or (iv) claims for Losses
the validity and amount of which will have been the subject of a final
judicial determination as described in Section 9.2(c) or (d), in each case,
the Indemnifying Party will pay such determined amount in immediately
available funds to the Indemnified Party by such means of payment as will be
requested by the Indemnified Party not less than one Business Day prior to
such payment, provided that if the Indemnified Party will be a Magellan
Indemnified Patty, (A) the Magellan Indemnified Party may, at its option,
receive all or any portion of such determined amount of Losses from and to the
extent of the Escrow Shares under the Escrow Agreement and (B) if the Magellan
Indemnified Party will elect to receive any portion of such determined amount
of Losses from the Escrow Shares under the Escrow Agreement, the Stockholders
and Magellan will deliver written instructions to the Escrow Agent in
accordance with Section 3.3 of the Escrow Agreement authorizing the payment of
such determined amount of Losses to the Magellan Indemnified Party from and to
the extent of the Escrow Shares under the Escrow Agreement.
(e) Within five Business Days of the termination or other
resolution of any claims for Losses specified in any Certificate, Magellan and
the Stockholders will deliver written notification, signed by each such party,
to the Escrow Agent of such termination or other resolution of such claims.
9.3 Limitations on Indemnification.
------------------------------
(a) The indemnification obligations of the parties hereto will
expire on the Indemnity Expiration Date, provided that such obligations will
survive with respect to, and to the extent of, any claim for which a
Certificate will have been delivered to the Indemnifying Party prior to such
Indemnity Expiration Date until such claim will have been finally resolved in
accordance with the terms of this Article 9.
(b) Neither Magellan nor any of its Affiliates' review of any
matters related to the transactions contemplated by this Agreement, including
any review of the business, assets, employees or the financial and other
condition of the Stockholders or the Company conducted by the officers,
employees, lawyers, accountants, consultants and other representatives or
agents of Magellan or any of its Affiliates, nor the knowledge of Magellan or
any of its Affiliates, or of any of such officers, employees, lawyers,
accountants, consultants and other representatives or agents, with respect to
any such matters, whether or not resulting from any such review, will affect
(i) the representations and warranties made by the Stockholders and the
Company in this Agreement, the agreements related thereto or any schedule,
exhibit, agreement, certificate or other document attached hereto or thereto
or delivered in accordance with the terms hereof or thereof, or (ii) the
remedies of Magellan or any of the other Magellan Indemnified Parties for
breaches of such representations and warranties.
30
<PAGE>
(c) Notwithstanding anything to the contrary in the foregoing,
no Stockholder shall be liable in respect of any indemnification obligation
pursuant to this Article 9 unless and until the aggregate cumulative amount of
Losses for which a Claim for indemnification pursuant to this Article 9 have
been made against all Stockholders under this Agreement exceeds the
Stockholder Basket, in which case the Stockholders shall be liable only for
such excess over the Stockholder Basket, provided that for purposes of
determining the claims for which Losses may be applied to the Stockholder
Basket, the representations and warranties contained herein shall be deemed
not to include any qualifications based on materiality or knowledge, and
provided, further, that (i) the aggregate indemnification obligations for the
Stockholders for a breach of a representation or warranty shall not exceed an
amount equal to the Purchase Price, (ii) each Stockholder's aggregate
indemnification obligations hereunder for a breach of a representation or
warranty shall not exceed an amount equal to the portion of the Purchase Price
to which such Stockholder is entitled pursuant to this Agreement.
(d) Notwithstanding anything to the contrary in the foregoing,
Magellan shall not be liable in respect of any indemnification obligation
pursuant to this Article 9 unless and until the aggregate cumulative amount of
Losses for which a claim for indemnification pursuant to this Article 9 have
been made against Magellan under this Agreement exceeds the Magellan Basket,
in which case Magellan shall be liable only for such excess over the Magellan
Basket, provided that for purposes of determining the claims for which Losses
may be applied to the Magellan Basket, the representations and warranties
contained herein shall be deemed not to include any qualifications based on
materiality or knowledge, and provided, further, that the aggregate
indemnification obligations for Magellan shall not exceed an amount equal to
the Purchase Price.
ARTICLE 10
MISCELLANEOUS
10.1 Consideration. None of the compensation received by any
-------------
Stockholder employee of the Company is separate consideration for, or
allocable to, any of their shares of Company Stock. None of the shares of
Magellan Stock to be received in connection with the Merger by any
Stockholder-employee of the Company constitutes separate consideration for, or
allocable to, any employment agreement. Any compensation paid to a
Stockholder-employee of the Company who performs services for Magellan or the
Surviving Corporation subsequent to the Merger will be for services rendered
and will be commensurate with the amount paid to third parties bargaining at
arms' length for similar services.
10.2 Notices. All notices, requests, demands and other communications
-------
pursuant to this Agreement will be in writing and will be deemed to have been
duly given and received (i) on the day delivered if delivered by hand, (ii) on
the day delivered if delivered by overnight courier, (iii) on the fifth day
following the deposit thereof in any general or branch United States Post
Office, enclosed in a registered or certified post-paid envelope, return
receipt requested, addressed to the address of the parties stated below or to
such changed address as such party may have fixed by notice, if delivered by
mail or (iv) on the day of transmission to the facsimile number stated below
or to such changed facsimile number as such party may have fixed by notice,
provided that receipt of such facsimile is confirmed by telephone, if
delivered by facsimile:
31
<PAGE>
If to the Stockholders or the Company,
addressed to such Stockholder or the
Company as follows:
Joe S. Galloway
1636 North Murdock Dr.
Pleasant Grove, Utah 84062
James H. Clark
432 North 750 East
Lindon, Utah 84042
Willis H. Clark
1065 North 1500 West
Provo, Utah 84604
BioSource, Inc.
1388 West Center
With a copy to:
If to Magellan:
Magellan Technology, Inc.
13526 South 100 West
Draper, Utah 84020
With a copy to:
Richard G. Brown
Kimball, Parr, Waddoups, Brown & Gee
185 South State Street, Suite 1300
Salt Lake City, Utah 84111
(801) 532-7750 Facsimile
Any notice of change of address will be effective only upon receipt.
10.3 Entire Agreement. This Agreement, including the Schedules and
----------------
Exhibits hereto, set forth the entire agreement and understanding between the
parties as to the subject matter hereof and merge and supersede all prior
discussions, agreements and understandings of every kind and nature between
them, and no party hereto will be bound by any representation, warranty,
covenant, term or condition other than as expressly provided for in this
Agreement.
32
<PAGE>
10.4 Governing Law. This Agreement and its validity, construction and
-------------
performance will be governed by the internal laws of the State of Utah
excluding principles of conflicts of law. This Agreement shall be deemed to
have been executed in the State of Utah, and shall be interpreted, construed
and enforced according to the laws of the State of Utah, without giving effect
to any conflict of laws provisions, and each party hereby expressly submits
themselves to the exclusive, personal jurisdiction of the courts situate in
the State of Utah, with respect to any and all claims, demands and/or causes
of action asserted or filed by any party in any way relating to, or arising
out of, this Agreement or the subject matter hereof. The Company and each of
the Stockholders hereby waives personal service of any and all process upon
itself, and consents that all such service of process be made by registered
mail directed to its address as described above and service so made shall be
deemed to be completed five (5) business days after the same shall have been
deposited in the United States mail, airmail, postage prepaid.
10.5 Severability. If any provision of this Agreement or the
------------
application of any provision hereof to any person or circumstances is held
invalid, the remainder of this Agreement and the application of such provision
to other persons or circumstances will not be affected thereby.
10.6 Assignability. Neither this Agreement, nor any of the rights or
-------------
obligations hereunder, may be assigned by any party hereto without the prior
written consent of the other parties hereto. This Agreement and its rights
and obligations will be binding upon and inure to the benefit of the parties
hereto and their respective successors and permitted assigns.
10.7 Counterparts: Headings. This Agreement may be executed in two or
----------------------
more counterparts, each of which will be deemed an original, but all of which
together will constitute one and the same instrument. This Agreement may be
executed by facsimile signatures, each of which will be deemed an original.
The headings contained in this Agreement are for reference purposes only and
will not affect the meaning or interpretation of this Agreement.
10.8 Survival of Representations and Warranties. The representations
------------------------------------------
and warranties of the Company, the Stockholders and Magellan contained in this
Agreement shall survive until the third anniversary of the Closing Date
whereupon they shall expire; except that (i) the representations and
warranties contained in Sections 2.3, 2.6, 2.40(b) and 3.2 shall survive
indefinitely, and (ii) the representations and warranties relating to any
liabilities in respect of Taxes shall continue beyond such period and shall
survive until the expiration of the applicable statute of limitation with
respect to such liability.
10.9 Public Announcement. Neither Magellan on the one hand, nor the
-------------------
Stockholders and the Company, on the other hand, will issue or permit any of
its Subsidiaries, stockholders, directors, officers, employees or agents to,
issue, any press release or public filing or other public announcement
concerning the transactions contemplated hereby without the prior written
consent of the other; provided, however, that nothing contained herein will
prevent the Stockholders, the Company or Magellan from furnishing any required
information to any governmental entity or otherwise complying with its legal
obligations.
33
<PAGE>
10.10 Expenses. Whether or not the transactions contemplated by this
--------
Agreement are consummated, all costs and expenses incurred in connection with
this Agreement and the transactions contemplated hereby (including without
limitation the fees and disbursements of the counsel, accountants or auditors
retained by each party or by any of the Option Holders in connection with the
negotiation, preparation, execution and performance of this Agreement, or any
other document, agreement or requirement contemplated by or resulting from the
transaction described in this Agreement) will be for the account of and paid
by the party incurring such costs and expenses.
10.11 Construction. This Agreement shall be construed as though all
------------
parties had drafted it.
ARTICLE 11
DEFINITIONS
11.1 Definitions. As used in this Agreement and in the schedules and
-----------
exhibits attached hereto, the defined terms set forth below have the
respective meanings set forth below (each such meaning to be equally
applicable to both the singular and plural forms of the respective terms so
defined).
"Affiliate": with respect to any Person, any other Person, directly or
indirectly, controlling, controlled by, or under common control with, such
specified Person.
"Business Day": any day other than a Saturday, a Sunday or a day on
which banks in the State of Utah are authorized or required by law to close.
"Claim": any claim, cause of action, investigation, suit or proceeding,
whether at law or in equity, or before any governmental department,
commission, board, agency or instrumentality, which involved a demand for any
judgment or liability.
"Closing": the closing of the transactions contemplated hereby as
provided in Section 1.6.
"Closing Date": As soon as possible after all of the conditions in
Articles 6 and 7 have been satisfied, but not later than October 31, 1997 or
such other date determined pursuant to Section 1.6 on which the Closing
occurs.
"Code": the Internal Revenue Code of 1986, as amended.
"Company": BioSource, Inc., a Utah Corporation.
"Company Balance Sheet": the balance sheet of the Company as at December
31, 1996 (including the notes and supporting information and schedules
thereto).
"Company Financial Statements": the Company Balance Sheet, and the
related statements of income and retained earnings and statement of cash flow
(including the notes and supporting information and schedules thereto) for the
fiscal year then ended, setting forth in each case in comparative form the
figures for the previous fiscal year of the Company, copies of which are
attached hereto as Exhibit F.
34
<PAGE>
"Company Stock": the shares of common stock, no par value per share, of
the Company.
"Effective Time": the effective time of the Merger, determined in
accordance with the provisions of the RUBCA.
"Employee Benefit Plan": any employee benefit plan, policy, arrangement
or agreement (including, without limitation, any savings, retirement, fringe
benefit, stock option, bonus, incentive compensation, deferred compensation,
excess, supplemental executive compensation, employee stock purchase,
vacation, sickness or disability, severance or separation, restricted stock
plan, policy or arrangement) or employment or consulting contracts or
agreements (including without limitation, any "employee benefit plan", as
defined in ERISA), whether or not subject to ERISA, whether written or oral.
"Employment Agreements": each of Employment Agreements, dated the
Closing Date, between the Surviving Corporation on the one hand and the Key
Employees on the other hand.
"Environmental Law": has the meaning set forth in Section 2.36.
"ERISA": the Employee Retirement Income Security Act of 1974, as
amended.
"Escrow Agent": Kimball, Parr, Waddoups, Brown & Gee (or such other
escrow agent selected by Magellan pursuant to the Escrow Agreement), acting in
its capacity as escrow agent under the Escrow Agreement.
"Escrow Agreement": the Escrow Agreement among Magellan, the
Stockholders and the Escrow Agent substantially in the form of Exhibit D.
"Exchange Act": the Securities Exchange Act of 1934, as amended.
"Indemnified Party": the party entitled to indemnification pursuant to
Article 9.
"Indemnifying Party": with respect to the indemnification provided
pursuant to Article 9, the party providing such indemnification.
"Indemnity Expiration Date": (i) the date on which the particular
representations and warranties of an Indemnifying Party expire as set forth in
Section 10.8 hereof; or (ii) with respect to covenants and agreements to be
performed hereunder, the date on which the statute of limitations runs with
respect thereto.
"Interim Balance Sheet": the balance sheet of the Company as at the
Interim Financial Statement Date.
"Interim Financial Statements": the Interim Balance Sheet and the
related statement of income and retained earnings and statement of cash flows
(including the notes and supporting information and schedules thereto) for the
seven month period ended July 31, 1997, setting forth in each case in
comparative form the figures for the corresponding period of the previous
fiscal year of the Company, copies of which are attached hereto as Exhibit F.
"Interim Financial Statements Date": July 31, 1997.
"IRS": the United States Internal Revenue Service.
35
<PAGE>
"Key Employees": James H. Clark, Joe S. Galloway, and Willis H. Clark.
"Lien": any lien, pledge, charge, security interest, encumbrance, title
retention agreement, adverse claim, option or other third-party interest or
claim.
"Loss": any cost, loss, damage, liability or expense (including, without
limitation, reasonable attorneys' fees, interest and penalties).
"Magellan Basket": $15,000.
"Magellan Indemnified Party": Magellan and its Affiliates, and the
officers, directors, stockholders and employees of Magellan and such
Affiliates.
"Magellan Stock": the common stock, par value of $0.0002 per share, of
Magellan Technology, Inc.
"Magellan Subsidiaries": ProHealth, Inc. and SkyHook Technologies, Inc.
"Material Adverse Effect": with respect to any Person, any event,
occurrence, fact, condition, change development or effect that has, or may
reasonably be expected to have, a material adverse effect on the business,
operations, properties, assets, condition (financial or other) or prospects of
such Person.
"Merger": the merger of the Company with and into ProHealth.
"Permitted Lien": (1) Liens listed in Section (i) of Schedule 1.1 and
reserved against in the Company Balance Sheet, but only to the extent so
reserved, (2) Liens listed in Section (ii) of Schedule 1.1 and reasonably
acceptable to Magellan; and (3) Liens for Taxes not yet due and payable.
"Person": a corporation, associations, partnership, organization,
company, business, individual, government or political subdivision thereof or
governmental agency.
"ProHealth": ProHealth, Inc., a Utah corporation.
"ProHealth Stock": the common stock, no par value, of ProHealth.
"Purchase Price": shall be the consideration received by the
Stockholders (the $150,000 cash payment and the 1,500,000 shares of Magellan
Stock).
"Return": any return, report, declaration, form, claim for refund or
information return or statement relating to Taxes, including any schedule or
attachments thereto or nay amendment thereof.
"RUBCA": the Revised Utah Business Corporation Act, as in effect from
time to time.
"SEC": Securities and Exchange Commission.
"Securities Act": the Securities Act of 1933, as amended.
"Share Conversion Amount": the meaning specified in Section 1.5(b).
36
<PAGE>
"Stockholder Basket": $15,000.
"Stockholders": James H. Clark, Joe S. Galloway and Willis H. Clark.
"Subsidiary": any company, association or other business entity, a
majority of the equity interest of any class or classes of which is owned,
directly or indirectly, by another person.
"Surviving Corporation": ProHealth, which shall survive the Merger.
"Tax": any federal, foreign, state, county, and local tax (including,
without limitation, income, gross receipts, excise, property, franchise,
license, sales, use, withholding, estimated, occupancy, capital, profits,
employment, unemployment compensation, payroll related, import duties and
other governmental charges and assessments), whether or not measured in whole
or in party by net income, and including deficiencies, interest, additions to
tax or interest, and penalties with respect thereto, and including expenses
associated with contesting any proposed adjustment related to any of the
foregoing.
"Tax Actions": claims, assessments, notices, proposals to assess,
deficiencies or audits with respect to any Taxes.
"To the knowledge of Company": the knowledge of the officers, directors
and all senior managers of the Company after due inquiry.
"To the knowledge of Magellan": the knowledge of the officers, directors
and all senior managers of Magellan and each of the Magellan Subsidiaries
after due inquiry.
11.2 Interpretation. As used in this Agreement, the terms "hereof",
--------------
"herein", "hereunder", and comparable terms refer to this Agreement in its
entirety and not to any particular article, section or other subdivision
hereof. Unless otherwise indicated, references in this Agreement to any
"Section", "Article", "Schedule" or "Exhibits" means a section or article of
this Agreement or a Schedule or Exhibit attached to this Agreement, as the
case may be.
37
<PAGE>
IN WITNESS WHEREOF, Magellan, ProHealth and the Company and
Shareholders have cause this Agreement to be duly executed and the Stockholder
have duly executed this Agreement, in each case, as of the day and year first
above written.
MAGELLAN, INC.
By: /s/ William A. Fresh
-----------------------------------------
William A. Fresh, Chief Executive Officer
PROHEALTH, INC.
By: /s/ William A. Fresh
-----------------------------------------
William A. Fresh, Chief Executive Officer
BIOSOURCE, INC.
By: /s/ Joe S. Galloway
-----------------------------------------
Joe S. Galloway, President
STOCKHOLDERS
/s/ James H. Clark
_____________________________________
James H. Clark
/s/ Joe S. Galloway
_____________________________________
Joe S. Galloway
/s/ Willis H. Clark
_____________________________________
Willis H. Clark
38
ROYALTY AGREEMENT
THIS ROYALTY AGREEMENT (the "Agreement") is entered into effective as of
October 1, 1997 by and between PROHEALTH, INC., a Utah corporation (the
"Company") and ________________, an individual residing at
_________________________ (the "Shareholder").
RECITALS
A. The Company, Shareholder, BioSource, Inc. and certain other
parties have entered into a Merger Agreement dated effective as of October 1,
1997 (the "Merger Agreement") pursuant to which BioSource, Inc. would be
merged with and into the Company;
B. Following the merger, the Shareholder will become an employee of
the Company. In connection with such employment, the Company and the
Shareholder desire to enter into a Royalty Agreement pursuant to which
Shareholder is to receive a royalty payment on the adjusted gross sales of
electrodermal screening equipment and enhancements by the Company.
C. The parties now desire to set forth the terms and conditions of
such royalty.
AGREEMENT
NOW THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto agree as
follows:
1. Royalty. Subject to the terms and conditions of this Agreement,
-------
including the termination of the royalty pursuant to Section 3, the Company
shall pay Shareholder (i) a royalty of one percent (1%) of the Adjusted Gross
Sales (as defined below) of the Company for the period commencing on October
1, 1997 and ending on September 30, 2000, and (ii) a royalty of one-half
percent (0.5%) of the Adjusted Gross Sales (as defined below) of the Company
for the period commencing on October 1, 2000 and ending on September 30, 2007.
For purposes of this Agreement, "Adjusted Gross Sales" shall mean the total
gross sales price for all electrodermal equipment, enhancements and
accessories sold by the Company during the relevant period less the sum of any
bad debt write-off and product returns during such period.
2. Payment of Royalty. The royalty shall be calculated and paid on a
------------------
quarterly basis commencing with the three month period ending December 31,
1997. Within 60 days of the end of each calendar quarter (90 days with
respect to the final quarter of the Company's fiscal year), the Company shall
(i) calculate the Adjusted Gross Sales for such calendar quarter and the
amount of the royalty, and (ii) deliver to the Shareholder a certificate
setting forth the calculation of the Adjusted Gross Sales and the royalty and
a check in the amount of the royalty payment. Shareholder shall notify the
Company within 30 days of receiving such information and royalty if he objects
or disagrees with the calculation of Adjusted Gross Sales or the royalty. The
Company and the Shareholder shall work reasonably and in good faith to resolve
any such objections or disagreements. If the Company and the Shareholder are
not able to resolve such objections within twenty (20) days after delivery of
1
<PAGE>
Shareholder's objections to the Company, then the issues in dispute shall be
submitted to the Company's independent certified public accountants (the
"Accountants") and the determination by the Accountants, as set forth in a
notice delivered to the Shareholder and the Company by the Accountants, will
be binding and conclusive on the parties. The costs and expenses of the
Accountants shall be borne solely by the Company if the determination reached
by the Accountants results in a change in the amount of the royalty of more
than 5% from the amount of the royalty finally determined by the Company prior
to submission of the disputed issues to the Accountants. The costs and
expenses of the Accountants shall be borne solely by Shareholder if the
determination reached by the Accountants results in a change in the amount of
the royalty of 5% or less from the amount of the royalty finally determined by
the Company prior to submission of the disputed issues to the Accountants.
3. Termination. The Shareholder hereby acknowledges that the Company
-----------
has granted this royalty conditioned upon the continued employment of James H.
Clark with the Company. The obligation of the Company to pay any royalty to
the Shareholder shall terminate on the earlier of (i) September 30, 2007, or
(ii) the date that James H. Clark's employment with the Company is terminated;
provided, however, that if James H. Clark's employment is terminated as a
result of death or disability or by the Company for any reason other than
"Cause", the termination date of the royalty shall be September 30, 2007.
Notwithstanding the termination of this Agreement and the royalty payable
hereunder, the Company shall be obligated to pay the royalty with respect to
Adjusted Gross Sales through and including the date of termination. In the
event the termination date occurs other than at the end of a calendar month,
Shareholder shall receive a pro rata portion of the royalty for such month
based on the number of days that have elapsed in such month prior to
termination. As used in this Section 3, the term "Cause" shall mean and
include (i) a material breach of the terms of employment, (ii) the commission
of an act of fraud or intentional misrepresentation, (iii) misappropriation or
conversion of assets or opportunities of the Company, (iv) the conviction for
any felony or other serious crime, (v) chronic alcoholism or drug addiction,
(vi) persistent failure to materially comply with written instructions from
the Company's Board of Directors or executive officers, (vii) a determination
by the Board of Directors that performance has been materially deficient, or
(viii) gross moral turpitude relevant to his office or employment with the
Company or affiliate of the Company .
4. Offset. The Company shall have the right to offset amounts
------
payable to the Shareholder hereunder by any liability of the Shareholder to
the Company or Magellan Technologies, Inc. under the indemnification
provisions of the Merger Agreement to the extent that such amounts have not
been satisfied pursuant to that certain Escrow Agreement between the
Shareholder and Magellan dated as of October 1, 1997 referred to in the Merger
Agreement.
5. Assignment. The rights of the Shareholder under this royalty may
----------
not be assigned without the written consent of the Company. Any attempt at
such a transfer, assignment, sale, pledge or encumbrance by Employee shall be
void ab initio.
6. Attorney's Fees. If a legal action or other proceeding is brought
---------------
by the Company or by the Shareholder for enforcement of this Agreement, the
party that prevails in enforcing this Agreement shall be entitled to recover
2
<PAGE>
reasonable attorney's fees, costs and expenses incurred, in addition to any
other relief to which they may be entitled.
7. Entire Agreement. This Agreement constitutes the entire
----------------
understanding between the parties hereto with respect to the subject matter
hereof and supersedes all negotiations, representations, prior discussions and
preliminary agreements between the parties hereto relating to the subject
matter hereof.
8. Cooperation. Each party hereto agrees to execute and deliver such
-----------
additional documents and instruments and to perform such additional acts as
any party may reasonably request or as may be reasonably necessary or
appropriate to effectuate, consummate or perform any of the terms, provisions
or conditions of this Agreement.
9. Governing Law. This Agreement shall be interpreted, construed
-------------
and enforced according to, and governed by, the laws of the State of Utah,
without giving effect to any conflict of laws provisions. Each party hereby
expressly submits themselves to the exclusive, personal jurisdiction of the
federal and state courts situated in Salt Lake County, State of Utah, with
respect to any and all claims, demands and/or causes of action asserted or
filed by any party in any way relating to, or arising out of, this Agreement
or the subject matter hereof.
10. Notices. Except when actual receipt is expressly required by the
-------
terms hereof, notice is considered given either (i) when delivered in person
or by facsimile or similar transmission to the recipient named as below, or
(ii) after deposit in the United States mail in a sealed envelope or
container, either registered or certified mail, return receipt requested,
postage prepaid, addressed by name and address to the party or person intended
as follows:
To the Company: ProHealth, Inc.
13526 South 110 West
Draper, Utah 84020
To Shareholder:
Either party may require, by notice given at any time or from time to time,
subsequent notices to be given to another individual person, whether a party
or an officer or representative, or to a different address, or both; provided,
however, that a P.O. Box shall not be considered to be an address for purposes
of this Agreement. Notices given before actual receipt of notice of change
shall not be invalidated by the change. Such recipient named must be an
individual person.
11. Waiver. Any waiver by any party hereto of any breach of any kind
------
or character whatsoever by any other party, whether such waiver be direct or
implied, shall not be construed as a continuing waiver of, or consent to, any
subsequent breach of this Agreement on the part of the other party or parties.
12. Severability. The provisions of this Agreement are severable and
------------
should any provision hereof be void, voidable or unenforceable under any
3
<PAGE>
applicable law, such void, voidable or unenforceable provision shall not
affect or invalidate any other provision of this Agreement, which shall
continue to govern the relative rights and duties of the parties as though the
void, voidable or unenforceable provision were not a part hereof. In
addition, it is the intention and agreement of the parties that all of the
terms and conditions hereof be enforced to the fullest extent permitted by
law.
13. Modification. This Agreement may not be modified except by a
------------
written instrument signed by all the parties hereto.
14. Counterparts. This Agreement may be executed in any number of
------------
counterparts each of which shall be deemed an original and as executed shall
constitute one agreement, binding on both the parties even though both parties
do not sign the same counterpart.
15. Headings. The headings of sections and subsections used in this
--------
Agreement are for convenience only and are not part of its operative language.
They shall not be used to affect the construction of any provisions hereof.
16. Interpretation. This Agreement shall be construed as though both
--------------
the Company and the Shareholder had drafted it.
4
<PAGE>
IN WITNESS WHEREOF, the parties have executed this Agreement to be
effective as of the date first set forth above.
"COMPANY"
PROHEALTH, INC.
By: ______________________________
Its:
SHAREHOLDER:
__________________________________
5
